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ABSTRACT
Background:
Non motor symptoms (NMS) have emerged as one of the key determinants of quality of life in 
people with Parkinson’s and fatigue is a common specific and distinctive NMS in PD but is often 
under diagnosed.
Aims:
In this body of work, I have attempted to explore firstly, the clinical correlates of fatigue, which 
may confound the characterisation of fatigue. Thereafter, the work has attempted to explore 
possible patho-physiological basis of fatigue in PD, addressing peripheral mechanisms such as 
cardiac sympathetic dysfunction within the spectrum of dysautonomia or centrally mediated 
mechanisms via striatal and limbic dopaminergic or serotoninergic pathways.
Methods:
In the first study, 135 non-depressed PD patients with an age range of 50-75 years and a clinical 
diagnosis of idiopathic Parkinson’s disease were studied using clinically validated scales and 
specifically the fatigue visual analogue scale initially to identify patients with central fatigue and 
those without. Collateral assessment of other confounders of fatigue chiefly depression and 
excessive daytime sleepiness were assessed by Non motor assessment sale (NMSS), Parkinson’s 
Disease Sleep Scale (PDSS), Epworth Sleepiness Scale (ESS) and Hospital anxiety and 
Depression Scale (HADS) In the following study, 20 patients from the above cohort with 
significant fatigue were further corroborated using the Parkinson fatigue Scale (PFS-16). Then
10 patients with high fatigue scores, fatigue +v patients ( PFS 16 score-> 8) and 10 patients 
with no fatigue , fatigue -ve cases ( PFS-16 < 8) were selected to undergo cardiac ^^^I-meta- 
iodobenzylguanidine (MIBG Scanning) (using validated local protocol as well as cardiac 2- 
methoxy isobutyl isonitrile (MIBI scans) to study the integrity of cardiac sympathetic 
innervation, a sensitive marker of autonomic function. Peripheral and central mechanisms have 
been investigated by using combination of clinical assessments with imaging parameters of 
SPECT and PET scans in selected subjects. Findings were correlated with clinical measures. In 
the final assessment study, 40 patients were selected from the original cohort for a Positron 
emission tomography (PET) scan sub study (20 fatigue +v cases (PFS-16 > 8) and 20 fatigue -  
ve cases (PFS-16 < 8)) Patients were matched for motor severity of PD and cases with significant 
depression or excessive daytime sleepiness were excluded. PET imaging was performed with 
18Fluoro-dopa (dopaminergic) and C-amino-4-(2-dimethylaminomethylphenylsulfanyl) 
benzonitrile (ll)C-DASB) (serotoninergic) ligands.
Results:
In the first study, fatigue correlated with disease severity as measured by Hoehn and Yahr (HY) 
staging which stratified the condition into three categories (HY l-2.5=Mild; HY 3=Moderate; 
HY 4+5 = Severe; Kruskal-Wallis test, p=0.004). There were no differences in fatigue levels 
between different subtypes of PD while anxiety, depression and sleepiness emerged as key 
clinical associations of fatigue.
In the second study, a pilot exploratory work, MIBG data from 20 non-depressed PD patients 
(53% male, mean age (mean ± SD) of 68.75 ± 9.7 years (range: 41-88 years), mean disease
duration 7.65 ± 5.5 years (range: 1-35 years) were analysed based on fatigue positive and 
negative cases (10 in each group) after a total assessment of 30 patients where scan was only 
possible in 20. The majority (51%) was at HY stage 2. Cardiac MIBG uptake was expressed as 
mediastinum to heart ratios at 15 min and 3 hrs (R1 and R2) and showed no difference between 
the fatigue versus non fatigue cases (Mean R1 of Fatigue Positive (1.6 ± 0.53) vs Mean R1 of 
Fatigue -ves (1.5 ± 1.37) and mean R2 of Fatigue Positives ( 1.58 ± 0.48 ) vs Mean R2 of 
Fatigue-ves ( 1.48 ± 0.23 )).
In the third stage PET data was analysed and Fatigue + cases showed, a significantly depressed 
uptake of 1IC-DASB binding in comparison to PD-Fatigue -  cases, in caudate, putamen, ventral 
striatum and thalamus (p<0.001, p<0.05, p<0.01, p<0.01; Mann-Whitney-Test) and fatigue 
severity was inversely correlated with 1IC-DASB binding. This is a novel finding never reported 
before. 18F-dopa uptake in the same structures was similar in the two groups using a region of 
interest approach, however, voxel-based statistical parametric mapping detected relatively 
reduced 18F-dopa uptake in caudate, thalamus and the insula in the PD-F group (p<0.001).
Conclusions:
Our preliminary data suggest, fatigue in PD is associated with anxiety, depression and sleepiness 
and appears to increase with disease severity although also evident in early-untreated phase of 
PD. The underlying mechanism is likely to be independent of peripheral sympathetic dysfunction 
as judged by cardiac sympathetic function but is associated with a severe loss of serotoninergic 
and dopaminergic innervation in the basal ganglia and limbic system (ventral striatum and 
thalamus) while sparing the raphe serotoninergic innervations. This suggests a dominant role of 
central serotonergic and in part, dopaminergic dysfunction in the origin of fatigue in PD.
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CHAPTER 1
THE IMPORTANCE OF NON-MOTOR SYMPTOMS IN PARKINSON’S DISEASE
1.1. Background
James Parkinson described Parkinson’s Disease (PD) in 1817, which is now recognised as one of 
the commonest chronic neurodegenerative disorders in the world and is the most prominent of 
disabling illnesses occurring chiefly later on in life^’l  James Parkinson also pointed out a range 
of non-motor symptoms (NMS) such as sleep problems, fatigue, pain, and bowel dysfunction as 
an integral part of PD in his essay. It is estimated that PD affects 1% of all people aged 70 years 
and above, but also affects younger subjects, accounting for 10% among people less than 50 
years of age. Typically the condition leads to depletion of dopamine containing and other 
(serotonergic, noradrenergic) neurons leading to the clinical expression of the classic motor 
symptoms of bradykinesia, tremor, and rigidity while NMS such as olfactory loss, depression 
and dysautonomia also dominate. However, while much has been achieved in relation to the 
motor syndrome of PD including the classic discovery of levodopa (L-dopa) being the treatment 
of choice for the dopamine depleted motor state of PD, little has been achieved in the arena of 
NMS of PD.
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This thesis will focus on the NMS of PD and in particular, fatigue, which is a key NMS of PD. In 
the chapters, I will begin with a short outline of the importance of NMS of PD, then try and 
unravel pathophysiological basis and prevalence in PD through a series of research-based 
studies. The current chapter is aimed to provide a short outline of the importance of NMS in PD.
1.2. NMS of PD; Epidemiology. Incidence, and Prevalence
The non-motor symptoms (NMS) of Parkinson’s disease (PD) are recognised as the key 
determinants of quality of life among people with Parkinson’s (PD) and their caregivers, but it 
continues to be under-recognised, under-declared and, consequently, under-treated in clinical 
practice^^’ The range of NMS that occurs in PD is complex and multifactorial, and are 
summarised in Table 1. While, in the clinic and in the research domain efforts have focused 
largely on the motor syndrome of PD, NMS have remained largely under-researched.
Table 1: The Spectrum of Non-motor Symptoms in Parkinson’s disease (Adapted from
Neuropsychiatrie symptoms
Depression & Apathy
Anxiety disorders
Delusions, Hallucinations and Psychosis
Compulsive behaviours
Cognitive dysfunction and Dementia
Sleep disorders
Restless Legs Syndrome/Periodic Limb Movements in 
Sleep
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Rapid eye movement sleep Behaviour Disorder
Excessive Daytime Sleepiness
Sudden Onset of Sleep and Insomnia
Autonomic dysfunction
Orthostatic hypotension
Post-prandial hypotension
Bladder disturbances
Sweating
Sexual dysfunction
Gastrointestinal Symptoms 
(overlap with ANS 
symptoms)
Sialorrhoea
Dysphagia
Nausea & Vomiting
Constipation & Unsatisfactory voiding of bowel
Sensory symptoms
Olfactory dysfunction
Visual disturbances
Pain & Abnormal sensations
Miscellaneous
Fatigue
Drug induced: impulse control disorders, hallucinations
Weight Changes
1.3. Pathophysiology
Recently, Heiko Braak and colleagues have reinforced the basis of NMS in PD by developing 
and publishing the concept of a six stage pathological process involved in Parkinsons disease 
with a “ bottom up” concepts'll The Braak hypothesis suggests that the process of PD begins at
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“induction sites” with degeneration of the olfactory bulb and the anterior olfactory nucleus 
(resulting in clinically olfactory dysfunction, a typical NMS in PD that is often the first clinical 
manifestation) at stage 1. In stage 2, the pathological process progresses to the lower brainstem, 
which involves brainstem nuclei '^^l. The nuclei involved in this process are key areas mediating 
NMS including olfaction, sleep homeostasis, depression and cognition, pain, Castro intestinal 
tract symptoms like constipation and central autonomic control^^l This pathophysiological notion 
ties in with the fact that several of these NMS are now recognised as possible pre-motor feature 
of PD as outlined in Table 2. Several neurochemicals and neurotransmitters are affected by the 
process of neurodegeneration in PD (Figure 1). These include dopaminergic, serotonergic and 
noradrenergic neurotransmission and in part all of this contributes to the non-motor symptoms 
complex of PD.
Fig 1: A diagram illustrating the various neurotransmitter linked pathways that can be 
affected
in PD ~
Table
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2: A list 
NMS
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suggested as pre-clinical (motor) feature in PD[2]
Strong Evidence:
Constipation
Olfactory deficit: (discrimination) 
REM behaviour disorder 
Depression 
Possible links :
Restless Legs Syndrome 
Apathy 
Fatigue 
Anxiety 
Pain
Male erectile dysfunction 
Visual disturbances (colour vision) 
Premorbid personality trends
The typical clinical motor symptoms of PD relates to Braak stages 3 and 4 when the Lewy body- 
related degenerative process involves the substantia nigra. However, it’s worth noting that the 
Braak staging is not without controversy, as the Braak theory is based on Lewy body formation 
and not specific neuronal degeneration; furthermore, why cognitive problems occur early, for 
instance in dementia with Lewy bodies or early PD have executive dysfunction, is not explained.
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1.4. Assessment of NMS
A key issue related to NMS of PD and particularly relevant to this thesis is that despite the 
importance of NMS in PD, research suggests that neurologists fail to identify NMS in over 50% 
of consultations^^l This has been highlighted recently in an international study conducted by 
Chaudhuri et al (2010) who reported that patients often fail to disclose NMS such as delusions, 
daytime sleepiness, intense and vivid dreams, and dizziness, and this under-recognition and non­
disclosure of NMS and can compromise treatment^^l
A recent development has been the development of validated tools for clinic and bedside 
assessment of NMS. The holistic tools, relevant to my thesis and NMS include the Non-Motor 
Symptoms Questionnaire (NMS-Quest) which is completed by the patient, and the Non-Motor 
Symptoms Scale (NMSS) completed by healthcare professionals. The NMS-Quest is a validated 
30-item self-completed screening tool, with a “yes/no” response format and was designed to 
empower patients to draw attention to the presence of NMS (Fig 2).
The NMSS on the other hand is a validated instrument, which categorises NMS into 30 questions 
into 9 domains and estimates the impact of NMS by weighing each symptom by frequency and 
severity Fatigue is a key question in this scale and can direct the examiner to specific 
examination with fatigue specific scales should this be flagged up in the holistic examination. 
There are other tools one can use too. These include the MDS-UPDRS, which among its motor 
assessments also includes some non-motor items as well as the SCOPA scales, which address 
some of the NMS in an individual basis
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1.5. NMS Prevalence
Holistic prevalence of NMS using validated tools has only been possible since 2006 when the 
NMS-Quest became available. Studies by Chaudhuri et al (2006) and Martinez-Martin et al 
(2007) showed that NMS was highly significantly prevalent in PD patients compared with age- 
matched controls, and a typical patient reported 10-12 NMS The NMSS also allows
prevalence studies being able to assess NMS in terms of frequency and severity and has been 
validated in two major international studies in over 600 patients and reports similar data as 
shown in Figure 3 and Table 4. Key prevalence studies addressing large number of patients and 
using validated tools are summarized in Table 3. These studies addressed PD patients across the 
full range of PD stages, from early to advanced disease. Fatigue was common across all stages as 
indeed are other NMS.
Figure 2: The NMS Questionnaire (NMS-Quest) [9]
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PD N M S QUESTIONNAIRE
N am e:......
Centre ID:
D a te :.....
Male □
Age:
Female □
NON-MOVEMENT PROBLEMS IN PARKINSON'S
T h e  m o v e m e n t  s y m p to m s  o f  P a r k in so n ’s  are w e ll k n ow n . H ow ever , o th er  p r o b le m s  c a n  s o m e t im e s  o c c u r  a s  
part o f  th e  c o n d it io n  or its  trea tm e n t. It is im p ortan t th at th e  d o c to r  k n o w s  a b o u t  t h e s e ,  p articularly  if th e y  are  
tr o u b le s o m e  for y o u .
A range o f  problems is listed below. Please tick the box ‘Yes’ if you have experienced it d u r in g  the past 
month. T h e d o c to r  or n u r se  m a y  a sk  you  s o m e  q u e s t io n s  t o  h e lp  d e c id e .  If y o u  h a v e  n o t  e x p e r ie n c e d  th e  
p ro b lem  in th e  p a s t  m on th  tick  th e  ‘N o ’ b o x . Y ou sh o u ld  a n sw e r  ‘N o ’ e v e n  if y o u  h a v e  h a d  th e  p rob lem  in th e  
p a s t  b ut n o t in t h e  p a s t  m on th .
Have you experienced any of the following in the last month?
Y es No
1. Dribbling of saliva during the daytim e..........................  □  □  16. Feeling s a d .‘low’ o r ‘blue’
Yes. n No□
2. Loss or change in your ability to taste or smell n □ 17. Feeling anxious, frightened or panicky.................. n □
3. Difficulty swallowing food or drink or problems 
with choking..................................................................... n □ 18. Feeling less interested in sex or moreinterested in s e x .................................... ............... n □
4. Vomiting or feelings of sickness (nausea)................. □ □ 19. Finding it difficult to have sex when you try .......... n □
5. Constipation (less than 3 bowel movements a 
week) or having to strain to pass a stool (faeces). n □ 20. Feeling light headed, dizzy or weak standing from sitting or ly ing ........................................ n □
6. Bowel (fecal) incontinence..................................... n □ 21. Falling....................................................................... □ □
7. Feeling that your bowel emptying is incomplete 
after having been to the to ilet................................. □ □ 22. Finding it difficult to stay awake during activities such as working, driving or eating..................... □ □
8. A sen se of urgency to pass urine makes you 
rush to the to ilet...................................................... n □ 23. Difficulty getting to sleep at night or staying asleep at n ight......................................................... n □
9. Getting up regularly at night to pass urine................ □ □ 24. Intense, vivid dreams or frightening dreams ... n □
10. Unexplained pains (not due to known conditions 
such as arthritis).............................................................. □ □
25. Talking or moving atxDut in your sleep as if you 
are 'acting' out a d ream .................................... n □
11. Unexplained change in weight (not due to
change in d iet).................................................................. n □ 26. Unpleasant sensations in your legs at night or while resting, and a feeling that you need to move . . . . □ □
12. Problems remembering things that have 
happened recently or forgetting to do th in gs...........
13. Loss of interest in what is happening around
you or doing th ings................................ ........................
□
n
□
□
27. Swelling of your le g s ..............................
28. Excessive sw eatin g........................................
2 9 .Double v ision ...........................................
□
□
□
□
□
□
14. Seeing or hearing things that you know or are 
told are not there....... ............................................... n □ 30. Believing things are happening to you that other people say are not tru e ........................................ n □
15. Difficulty concentrating or staying fo cu sse d ............ □ □
All the information you supply through this form will be treated with confider^ce and will only be used for the purpose for which it has been 
collected. Information supplied will be used for monitoring purposes. Your personal data will be processed and held in accordance with the 
Data Protection Act 1998
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Figure 3: Prevalence of NMS in PD patients (blue) versus controls (red) in the original 
NMSQuest validation international study. Data is from Chaudhuri and Martinez-Martin 
and Chaudhuri et al
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1.6. NMS: Importance and Conclusion
I have tried to highlight the fact that a number of recent studies suggest that NMS are common in 
patients with PD across all stages of the disease and possibly pre-date the motor development of
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PD. Parkinson’s occurs worldwide^ '^^  ^and NMS have a key role in the determination of quality 
of life of people with Parkinson’s but this aspect continues to be under-reported and overlooked 
as clinicians focus on motor features^^^’ Treatment of Parkinson’s often leads to fluctuation in 
motor responses. However, an important aspect of the natural history of PD is also the fact that 
these fluctuations are often associated with NMS known as non-motor f luctua t ionsFat igue  is 
a key aspect of the range of NMS that occurs in PD as shown in the holistic prevalence studies 
outlined in Table 3. Fatigue also forms part of aspects of non-motor fluctuation in PD^ ^^  and as 
such, the role of treatment in attenuating fluctuations in PD also needs to be highlighted. Like 
many NMS, fatigue is under-recognised and can occur very early in PD. This thesis will deal 
with issues around prevalence of fatigue in PD across a range of stages, as well as possible 
patho-physiological bases of this symptom.
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CHAPTER 2
FATIGUE -  PARKINSON’S DISEASE
2.1. Fatigue
In lay terms, fatigue can be described as being an '’overwhelming sense o f tiredness, lack o f 
energy and feeling o f fatigue’^^ \^ Fatigue may be a normal phenomenon and in healthy adults, 
fatigue can manifest as a transient phenomenon brought about by prolonged exertion or exercise, 
which usually diminishes with rest and is not intrusive to daily functioning However, disease 
related or pathological fatigue is different and is a chronic condition which could be brought on 
by no or minimal exertion and does not fully improve with rest. In addition, this variant or 
expression of fatigue leads to considerable disability and distress Pathological fatigue is most 
frequently associated with a variety of disease states either as a primary or secondary 
manifestation of the illness and can be reversible for example; fatigue in cancer patients is 
frequently secondary to anaemia and responds to anaemia treatment
The experience of fatigue is not restricted to patients who suffer from a chronic medical 
condition (i.e. diabetes mellitus) or a psychiatric illness (i.e. depression). Those who are 
‘medically fit’ and have no pathological disturbance can also experience fatigue. A large 
proportion of primary care visits from the general population, approximately 10% are for the 
complaint of fatigue
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What is fatigue and how can it be diagnosed therefore, remains a clinical challenge and is a 
dilemma with which clinicians and patients alike, battle. What is known about fatigue is that it 
has a substantial effect on a health related quality of life (HRQoL) of patients. Fatigue is not 
strictly quantifiable and can be described as a disruption of functionality within a continuum. 
This makes it hard for both clinicians to diagnose fatigue and for patients to explain the extent of 
their debilitation. Fatigue is a subjective symptom and what is often illustrated as debilitating for 
one patient may be bearable for another
Fatigue is a major clinical problem in many medical conditions, especially neurological 
conditions such as multiple sclerosis (MS). James Parkinson himself recognised the issue of 
fatigue in Parkinson’s in his initial classic description of this condition in 1817^ *^  although it is 
only in 1993 that and Van Hilten et al published on the association and importance of fatigue in 
PD
It is commonly perceived that the usual secondary causes of fatigue in individuals with PD are 
likely to be sleep disorders such as excessive daytime sleepiness (EDS), centrally active 
medications and depression But some population-based studies in PD have shown that sleep 
disorders such as excessive daytime somnolence and depression do not account for fatigue 
in the majority of PD subjects with fatigue. Similarly, studies of the common dopaminergic 
medications used in PD show little effect while some may even improve fatigue, despite EDS 
associated with these same medications To confound the issue further, several studies have 
demonstrated a correlation between measures of depression and fatigue but this may in part be 
due to methodological issues related to the overlap of symptoms assessed by fatigue and 
depression inventories It is worth noting that even in studies, which report a correlation of
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depression and fatigue, about 50% of patients without depression, still report fatigue Little is 
known about the natural history of fatigue in PD and some longitudinal studies suggest that PD 
patients with fatigue continue to have fatigue throughout the advancing stages of PD, while those 
without fatigue generally do not develop it The evidence is therefore that in most people with 
Parkinson’s, fatigue is intrinsic to the disease process and not a secondary phenomenon.
2.2. Classification of fatigue
Ryan classified fatigue to two distinct components: (a) subjective fatigue which implies a 
feelings of tiredness, weariness or exhaustion and (b) objective fatigue which refers to a 
reduction in the capacity to perform a task as a result of continuous performance on the same 
task
Objective fatigue, by definition, always affects performance on the task that induced the fatigue 
and may affect performance on other tasks however, distinct components of this complex 
symptom has not been identified. Work in animal models have suggested that structures within 
the central nervous system (CNS) may act as a ‘central governor’ to prevent total energy 
depletion which may express itself as objective fatigue This may be otherwise termed central 
fatigue. Potential pathways may include inflammatory (interleukin-6), metabolic (cerebral 
glycogen depletion) and neuronal (increases of serotonin and decreases of dopamine) 
mechanisms and hypothalamus has been suggested as at least one of the CNS structures 
responsible for fatigue, at least in rat models Of relevance is the fact that PD is known to 
affect the hypothalamus and thus could explain the existence of central fatigue in PD.
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Another key aspect of fatigue is psychological and it is conceivable that fatigue could be 
resultant from emotional factors, which may influence both subjective and objective fatigue. 
There have been consistent reports of fatigue being associated with depression in PD and thus it 
seems reasonable to posit that mood is a contributor to subjective fatigue. Depression and 
chronic fatigue syndrome are also associated with each other and often include pain^^^l To 
support this observation, studies in healthy subjects have shown that objective performance and 
subjective fatigue may be altered by giving false temporal or force feedback during their 
performance suggesting a strong psychological component Increased comorbidity of the five 
nonmotor symptoms Anxiety,depression,fatigue,sleep,sensory symptoms were associated with 
greater PD severity &can occur in same patients^^^^
roadly therefore, central fatigue refers to decrements in task performance due to pathological 
changes within the CNS and most likely in the hypothalamic and limbic areas There are 
few neuropsychological studies in this domain and studies of cognitive fatigue in multiple 
sclerosis (MS) have suggested that central fatigue in clinical populations may disproportionately 
affect specific neuropsychological domains however, there are no studies to date that have 
examined central fatigue in PD using cognitive tasks. Based on the evidence base available it is 
reasonable to assume that central fatigue in PD may be caused by alterations of global energy 
expenditure or dysfunction within basal ganglia circuitry
Fatigue may also exist in a peripheral form and peripheral fatigue refers to performance 
decrements on the basis of dysfunction at the level of muscle or peripheral nerves. This 
commonly acknowledged fatigue is typically brought on by physically demanding motor tasks 
involving repetitive or prolonged muscle contractions and can occur in many diseases of the
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peripheral nervous system and muscle Distinctive and specific physiological and cellular 
mechanisms of peripheral fatigue have been proposed on the basis of direct electrical 
stimulations of nerve and muscle in humans but studies in PD are lacking In spite of the 
apparent differences however, the distinction of peripheral from central fatigue remains difficult 
and challenging and this is also likely to be the case in Parkinson’s.
2.3. Prevalence in PD
Fatigue is a dominant problem in MS, affecting about 75% but is also common in anaemia, 
congestive heart failure, systemic lupus erythematosis, cancer patients receiving chemotherapy, 
and is a cardinal sign in the DSM-IV diagnosis of major depression and anxiety Therefore, 
because of the common occurrence of depression and anxiety in PD, prevalence studies are 
especially difficult to address primary fatigue from fatigue secondary to these problems. Taking 
into account varying methodology, definitions and patient sample, studies report a prevalence 
between 33% and 58% of the population surveyed In the first published study by Van Hilten 
and colleagues, fatigue was reported to be considerably more common in PD patients than in 
controls, affecting nearly 50% of their sample Subsequently in an US study of 100 
consecutive PD patients, 50% stated fatigue to be one of their three most disabling symptoms 
while one-third listed fatigue as their single most disabling symptom (Table When
interviewed, the majority of patients described their fatigue with PD as different from their 
experience of fatigue prior to developing PD.
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Table 4: Percentage of patients with PD that described fatigue as a debilitating symptom. 
Information taken and compiled from Friedman et al[22].
Fatigue is the most debilitating symptom of PD 33%
Fatigue is one of three most debilitating symptoms in PD 58%
igue in PD is experienced as different to fatigue experienced 
before the onset of PD
67%
There is
also evidence of fatigue preceding the motor diagnosis of PD and van Hilten et al had reported 
that 43% of PD patients suffered from fatigue and 50% of this cohort had noted that the fatigue 
had predated the onset of motor symptoms In this study while, 15% of patients rated fatigue 
as their single worst symptom, 54% considered it as severe as their other parkinsonian 
symptoms. Karlsen et al carried out a case control Norwegian study of 233 PD patients and 
reported that 44% were fatigued versus 18% of the controls Both this study as well as the US 
study above, showed a correlation of fatigue with depression, but not disease severity. In the 
controls without depression, dementia or sleepiness also increased rates of fatigue was noted. 
However, in another US study from the University of Maryland reported that fatigue affected 
40% of a selected group and was not associated with gender or disease severity but, unlike other 
reports, this study found no association with depression This study also addressed physician 
awareness of NMS as a whole and reported that over 80% of PD patients complaining of 
significant fatigue did not have their fatigue recognised by their PD specialist neurologists.
Medication effects in PD and the issue of fatigue are particularly important. The multicentre 
ELLDOPA trial was designed to determine whether L-dopa altered disease progression, and as a 
secondary measure the fatigue severity scale (FSS) was included These were untreated, non­
demented, non-depressed patients with early PD, not yet requiring dopaminergic therapy and
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even in this sample the point prevalence of fatigue was greater than 33%, with 127 of 349 
subjects endorsing fatigue prior to any treatment.
There have been more recent “holistic” large-scale multicentre studies addressing the point 
prevalence of fatigue in Parkinson’s using validated tools such as the NMSS and the PRIAMO- 
questionnaire with prevalence rates varying from 33% to 80% (Tables 5 and
Authors Year Prevalence (%) Comments/Premotor Reference
Hoehn and Yahr 1967 2 [44]
Van Hilten et al. 1993 Study 1:48% 15% worst [41]
Study 2: 43% 50% premotor
Friedman and 1993 l/3rd Most disabling
Friedman
Karlsen et al 1999 44.2% [42]
Shulman et al 2002 42% Recognised in 14% only [7]
Helofson and Larsen 2002 80% PD V 20% C C incl chr arthritis [45]
Martinez-Martin et al 2006 67.6% [46]
Sullivan et al 2007 72% Treated in 6% only
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Schifitto et al 2008 37% Mental Fatigue 38.8% [43 ]
(Elldopa study analysis) Physical fatigue 40.1 %
Hagell and Brundîn 2009 32% reports Before motor [47]
disturbance
Table 5: A summary of prevalence figures for fatigue in Parkinson’s disease from 
published studies.
Table 6: Table taken from the PRIAMO study by Barone et al showing an overall 
prevalence of fatigue in 58.1% of the population (n=1072) studied.
NONMOTOR SYMPTOMS IN PD
TABLE 3. Prevalence cf NMS domains and disease stage
1645
NMS domains
All
Disease Stage (Hoehn and Yahr scale)
1 1.5-2 2.5-3 4-5
N = 1.072 (%) N = 167 m N = 515(91) N =325 (%) N = 49 (%)
Gastrointestinal 654 (61.0) 76 (45.5) 280(54.4) 250 (769) 36 (73.5)
Pain 653 (60.9) 85 (50.9) 302 (58.6) 218(67.1) 39 (79.6)
Urinary 614 (57.3) 72 (43.1) 266 (51.7) 222 (6&3) 44 (89.8)
Cardiovascular 158(14.7) 22(13.2) 70(13.6) 53(163) 11 (22.5)
Sleep 687(64.1) 80 (47.9) 312 (60.6) 245 (75.4) 40(81.6)
Fatigue 623 (58.1) 63 (37.7) 291 (56.5) 224 (68.9) 40(81.6)
Apathy 328 ( 30.6) 41 (24.6) 138 (26.8) 119(366) 24 (49.0)
Attention/memory 479 (44.7) 63 (37.7) 208 (40.4) 168 (51.7) 32 (65.3)
Skin 260 (24.3) 24(14.4) 102 (19.8) 112 (34.5) 16 (32.7)
Psychiatric 716(66.8) 102 (61.1) 326 (63.3) 238 (73.2) 41 (83.7)
Respiratory 191 (17.8) 16 (9.6) 80(15.5) 74 (218) 15 (30.6)
Miscellaneous 515 (48.0) 62(37.1) 247 (48.0) 168 (51.7) 29 (59.2)
Cochran-Atmituge trend test <0.0045 (with Bonferroni's collection) for all NMS except cardiovascular symptoms { P =  0.0774).
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2.4. Natural History
Little is known of the natural history of fatigue in PD. The cohort from the original US study of 
Friedman and Friedman were followed up and at nine years follow up, the patients who were 
initially fatigued remained fatigued, but were worse in terms of severity However, only a few 
patients who were not initially fatigued developed fatigue as the disease progressed thus 
implying that fatigue is an early feature of PD and it remains constant throughout the disease 
course. In the larger Norwegian study, patients were followed for 8 years using the Nottingham 
Health Profile and reported that only 56% of those initially fatigued were fatigued at follow-up 
measurements at 4 and 6 years and an increasing prevalence was observed
A wide variation in data re prevalence and natural history related to fatigue therefore exists. This 
could be due to the fact that till recently, there was no consistent way in which fatigue was 
defined. This fact highlighted the need to construct a universal scale for an accurate diagnosis.
2.5. Clinical Measurements of Fatigue
Subsequent to the above observations, a variety of clinical scales with which it is possible to 
measure fatigue in neurological diseases have been devised and validated. As mentioned before, 
different scales use different definitions of fatigue and as a result of this, there have been 
inconsistencies in the diagnoses of fatigue as a complication of PD.
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One of the first ones is The Fatigue Severity Scale (FSS), developed by Krupp and colleagues 
are a well known 7-stage query-type evaluation, which is composed of 9 questionnaires. This has 
been widely used in medical research. The main disadvantage with the use of this scale is that it 
cannot be used for people of all ages owing to its limited questionnaire entries
The Parkinson Fatigue Scale (PFS-16)*^ '^ ^^  is a specific measure designed to evaluate fatigue in 
PD. It is a 16-item scale focused on the physical aspects of fatigue and their impact on patient’s 
functioning. Its authors deliberately exclude emotional and cognitive features because they may 
occur independently of fatigue in the PD setting. In the original article, satisfactory metric 
properties were found and cut-off points for presence of and limitations by fatigue are suggested.
Fatigue Impact Scale for Daily Use (D-FIS)^ ^®^  is an eight-item self-assessment scale derived 
(using Rasch analysis) from the Fatigue Impact Scale and developed for a daily follow-up of 
physical and mental fatigue. The D-FIS is not a specific instrument for PD, but it has been 
partially validated in PD patients and has been used in PD patients The scale is easy to apply 
and designed for daily follow-up, thus making the scale attractive for use in clinical research and 
clinical monitoring of patients.
Other non-specific scales, which have been applied for assessment of fatigue in PD, are the 
Fatigue Severity Scale, Fatigue Assessment Inventory, Rhoten Fatigue Scale, Multidimensional 
Fatigue Inventory, Functional, Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F), 
and visual analogue scales.
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The Movement Disorders Society convened a task force to critically analyse the clinimetric 
aspects of the several scales available for assessment of fatigue and Table 7 is taken from this 
article and lists the recommended and suggested scales for severity rating of fatigue as well as
screening [51]
Table 7: Comparative analysis of fatigue rating Scales as published by the Movement 
Disorders task force on rating scales.
TABLE I . Fatigue Rating Scales review
Scale name
#
Items
Time required 
est imated
Definition 
of fatigue 
provided
Time
frame* Problems
No of pdnts 
for severity 
rating
Endorsement 
for severity 
rating
Endorsenient 
for screening
FAl 29 10-30 yes 2 wk Lengtliy 7 Suggested Suect-stcd
FSS 9 5 Nt> 2 wk None 7 RfrCOrimi ended RèCürnnièiided
FA C IT F 13 5 Nu 1 wk None S Su cues ted Recommended
MR in lo-in No ‘ l.ftlelv’ I .rtigth 5 Res'ïitnitifTideii Siirno.eOe.d
PFS 16 15 No 2 wk Requires binary format 2 or 5 Suggested Recommended
D-ns s 5 Yes Today None 5 Suscested Listed
FSl 33 20-30 No Not stated Lengtli: lack of validation 7 Listed Listed
VAS 1 1 Variable'^ Variable* Lack of validation Continuous Listed Listed
CGI I 1 Variable^ Variable* Lack of validation Variable Listed Listed
♦Time frariK =  lirtte frante iii wliicli faiigue is as.^ssal; liiiie requjred =  ftr lesitnc,. iii niin.
T l i s  CGI a id  VA S aie lu t staiidaidiad. tlititfoic.fiiligtit may le  dsfm tdoi lu t ami .study i i ic n a la k o  may be defiied aibitfaiLly \vit]iiiica-:!istudv. 
KdIc tlial vvliilc “ reeormiicudcd" cvtmmcs a higher level o f  cndorscmcnL in mo-st o f  the above scales, tlic lack o f tliia designation is due to  lack of 
data on scnsilivitv to cliance in PD.
2.6. Role of the Basal Ganglia in Fatigue
Basal ganglia are a group of nuclei of varied origins that are present in the brains of vertebrates 
and work as a cohesive fimctional unit. Basal ganglia are situated at the base of the forebrain and 
are perfectly connected with the cerebral cortex, the thalamus, and other important areas in the 
brain. These are associated with several functions, including the voluntary motor control,
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procedural learning functions that are related to routine, and apparently simple bodily behaviors 
as well as cognitive, emotional functions that arise from the cortex of the brain and its periphery. 
This process has its own flow and processing that gets disturbed when lesions occur. These 
lesions are caused mostly due to biochemical fluctuations in the neurotransmitter-balanced 
levels. The usually smooth and integrated process of a limbic type (emotional and motivational) 
and motor functions go completely haywire. These fluctuations have the solid ability to bring the 
body to a screeching halt in terms of the day-to-day physical tasks and mental-emotional 
activities done by the person concerned. Patients in such situations are unable to function 
normally and experience severe and unexplained fatigue.
This diseased condition of the body is accompanied by a loss of nigrostriatal dopamine. The 
body also experiences cellular loss in a few non-motor paths related to dopamine like the 
mesolimbic as well as mesocortical dopamine sections. The noradrenaline or the locus coeruleus 
and the serotonin or the median raphe sections that project towards the frontal and limbic 
regions. A study was conducted to understand if basal ganglia did, in fact, bring about fatigue 
and tiredness in PD patients The research also found that patients complaining of too much 
tiredness exhibited lower than the normal levels of putamen glucose metabolism. Another 
research study showed how bilateral pallidotomy in the disease was accompanied by extreme 
tiredness, sleepiness, behavioral changes, and lack of interest in most activities despite better 
functional capacity of motor functions
2.7. Quality Of Life and fatigue
A study conducted by Herlofson and Larsen et al investigated the impact of PD in patients who 
complained of fatigue, compared with those who did not have symptoms of fatigue^^^l Patients
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who complained of fatigue symptoms had reduced HRQoL scores, which showed a correlation 
between fatigue and an impaired HRQoL score. This study also showed differences in the two 
patient groups when considering physical and social functioning, mobility and emotional 
welfare^ "^ ’^ Larsen et al. conducted a community-based study which showed that patients who 
suffered non-fluctuating PD scored worse on the HRQoL scale than both, people who were 
healthy, elderly and who had age-related fatigue, and those who suffered diabetes mellitus and 
thus were afflicted with chronic disease-related fatigue^"* l^ Several studies have subsequently 
confirmed poor quality of life in Parkinsonian patients with fatigue '^^ ’^
2.8. Unmet needs in relation to the pathophysiology of Fatigue in PD
Little is still known about the origins of fatigue in PD particularly central fatigue and animal 
model studies have suggested a possible dopaminergic and serotoninergic origin possibly 
combined with mitochondrial respiratory chain related problems in the muscle. The basal ganglia 
and the hypothalamus as well as the limbic systems may play a central role and the contributions 
of a ''basal ganglia and striato-thalamo-cortical loop” has been hypothesised, as noted 
previously. The evidence that in some patients, the experience of physical fatigue can be 
improved by dopmainergic therapy such as L-dopa further highlights the relationship between 
fatigue and neurotransmitter depletion in PD.
An association of cardiovascular function/ disorders with fatigue has been noted and fatigue is 
common in many cardiovascular disorders including post myocardial infarction states. Fatigue is 
also expressed in patients suffering from significant postural hypotension, a dominant sign of 
autonomic dysfunction, in particular, sympathetic nervous system failure. As cardiovascular 
autonomic dysfunction is prominently reported in PD, and as this can be reliably investigated
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using cardiac MIBG (^^^I-meta-iodobenzylguanidine) scanning, it would be a reasonable to 
investigate whether this correlation is valid in PD.
In the following chapters I describe a series of studies addressing the unexplored or poorly 
defined issues related to fatigue in Parkinson’s. Broadly this will address the following issues:
i. A point prevalence in a sample of PD patient undergoing “holistic” non motor studies under 
the guidance of Professor K Ray Chaudhuri, so as to correlate the presence of fatigue with 
known confounders such as excessive daytime sleepiness/sleep disorders, depression and 
other disease demographics. A conformation of correlation of fatigue with quality of life 
measures will be sought.
ii. Identifying a subset of patients from the above study, who have fatigue and then comparing 
them to a group without fatigue (also from above study) who are matched and free of 
depression and examined by cardiac MIBG scanning. This will explore the hypothesis as to 
whether a component of fatigue may be underpinned by cardiac sympathetic dysfunction, 
which may be a marker for autonomic dysfunction in PD.
iii. Finally I will address a central nervous system (CNS) patho-physiological basis of fatigue in 
PD. This work will be pursued in collaboration with the positron emission tomography (PET) 
imaging centre at the Hammersmith Hospital, Imperial College with Professor David J 
Brooks and Dr Nicola Pavese. In this work I will select 2 groups of matched PD patients with 
and without fatigue from the first study and perform PET scans using ligands that mark the 
central dopaminergic and serotonergic systems in an effort to unravel whether these 
neurotransmitter systems in the CNS are abnormal in PD patients with fatigue.
Such a set of imaging and clinical studies, using CNS and cardiac imaging in PD patients with 
fatigue has never been attempted before.
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CHAPTERS
A CLINICAL STUDY OF FATIGUE AND ITS CORRELATES IN PARKINSON’S 
DISEASE
Related paper:
V Metta, K Logishetty, P. Martinez Martin, Heather M. Gage, P.E.S. Schartau, T.K 
Kaluarachchi, Anne Martin, Per Odin, P. Barone, Fabrizio Stocchi, A. 
Antonini, K Ray Chaudhuri, The possible clinical
predictors of fatigue in Parkinson’s disease: a study of 135 patients
as part of international non motor scale validation project. Parkinson’s Disease 2011’. 
Volume 2011, Article ID 125271,1-7. doi:10.4061/2011/125271.
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3.1. Introduction
Parkinson’s disease or PD is a degenerative disease affecting the central nervous system with 
clinically dominant motor symptoms which include tremors, rigidity, bradykinesia, and unstable 
posture^^l However, as discussed earlier, the NMS are an integral aspect of Parkinson’s and 
represents the “hidden symptoms” of PD. The NMS are common, occurring in up to 98% of 
subjects and often under-reported in patients with PD^^ l^ Several studies have now reported that 
the burden of NMS are the key determinants of the quality of life in PD patients^^^l
Fatigue, a state of overwhelming exhaustion, has emerged as a key NMS of Parkinson’s, and 
studies show that fatigue could be reported in early PD as well as advanced PD, complicating 
late disease and often posing an overwhelming problem for patients and relatives^^^’ A  large 
Italian holistic study of NMS in PD, the PRIAMO study reported fatigue to be prevalent in 
58.1% of a population sample of 1072 patients ranging from 37.7% in early (Hoehn and Yahr 
(HY) stage 1) PD to 81.6% in the advanced (HY stage 5) stage^ ^^ .^ Friedman investigated 
patients with fatigue and reported that fatigue was the most “disabling” symptom in 33% while 
50% reported troublesome fatigue^^^ .^ Specific scales for clinical assessment of fatigue have now 
been validated for PD and these have also established fatigue to be an independent NMS of PD 
although in clinical practice fatigue may be confused with excessive daytime sleepiness or 
depression^^^l Using one of these scales, one could explore the clinical associations of fatigue in 
PD such as disease severity, anti-parkinsonian medications and other NMS like depression, 
apathy, and excessive daytime sleepiness etc. In this clinical study we have attempted to 
investigate the background of the validation work of the non-motor scale performed by the 
International PD non-motor group with a patient base of 135 cases. Clinical data in relation to
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disease state and severity was collected along with motor and a range of non-motor data along 
with a focus on fatigue based assessments.
3.2. Ethical approval
The project was approved as part of the non-motor scale validation study by the research ethics 
committee of Lewisham hospital NHS Trust.
3.3. Methods
Patients were included in the study after informed consent as part of the non-motor scale and 
questionnaire validation protocol under the auspices of the PD non motor group. Patients were 
recruited from the National Parkinson Foundation centre of excellence at Kings College Hospital 
along with PDNMG contributory centres in Spain, Germany, Italy and Scandinavia. In line with 
all PD non motor group studies, all data was anonymised and collected at a central database at 
Kings and Lewisham hospitals and analysed at the National Centre of Epidemiology in Madrid, 
Spain.
3.4. Patients
Patients from all disease stages (HY stages 1-5) were included and comprised of those with 
idiopathic PD as defined by the UK Brain Bank criteria for diagnosis of Parkinson’s Other 
exclusion criteria included:
1. Significant general medical comorbidities of hypertension, diabetes, ischaemic heart 
disease which may be confounders for fatigue
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2. Patients with bipolar disorders, severe depression (based on scores of hospital anxiety 
and depression rating scale (HADS), depression according to the Hamilton Rating Scale 
for Depression (scores > 13)).
3. Patients with dementia or cognitive impairment as determined by a minimental scale 
score of < 24 as this will pose problems with self reporting of symptoms which would be 
required for this study.
3.5. Assessment base
The main clinical base of this work was centred around the weekly outpatient clinics at the 
National Parkinson Foundation Centre of Excellence at Kings college Hospital NHS Foundation 
Trust and satellite clinics at Lewisham hospital NHS Trust. These clinics cover tertiary regional 
clinics as well as clinics with direct referral from the primary care and as such the population 
included is representative of PD population at large and ranged across various stages of PD so 
that we could include patients at HY stage 1 to 5 and with varying disease durations^^^l 
Additionally, we were also able to recruit untreated drug naïve patients sent to the clinic for 
diagnosis and treatment.
3.6. Assessment tools
The battery of scales and questionnaires included self-reporting ones as well as those completed 
by the clinician/healthcare professionals and have been well described in several publications 
from the centre of excellence by Professor KRC and his team during the validation studies of 
NMS questionnaires and scale^^’ Use of the NMSS (figure 4) was integral to the study and 
involved training sessions under the supervision of KRC. Fatigue is measured by item 4 of the 
second domain of NMSS and rated by severity and frequency. When fatigue was constant,
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frequency was rated as 4 (most frequent). Patients and careers were first approached and the need 
for the study explained. Following verbal and informed consent, patients, with the help of careers 
completed the “patient completed assessments” including, PD questionnaire (short form, PDQ-8) 
as well as HADS^^^l This was completed in approximately 25 minutes and care was taken to 
avoid patient overload. Thereafter, assessments were completed in an objective manner by 
myself and this took another 35-40 minutes and included assessment of patient demographics 
(age, duration of disease, medication history, screening for comorbidities), the motor state (motor 
severity of disease as assessed by HY stage and the old version of the unified Parkinson’s 
disease rating scale (UPDRS)^ ^®^ .
Non-motor issues relating to fatigue were addressed additionally, by a fatigue visual analog scale 
(VAS) for this study. The fatigue VAS is used by interacting with the affected persons with 
specific emphasis on the severity of the tiredness they experienced using the VAS where 0 on the 
scale signified highest amount of fatigue and 100 signified complete absence of tiredness. This 
scale known as the fatigue impact scale for daily use fatigue impact scale for daily use (D-FIS) 
has been validated for Parkinson’s and its clinimetric details have been published The D-FIS 
has 8 items and takes 5 minutes to complete and relates to fatigue experienced on the day of 
examination. Severity is rated in 5 points and the scale has no problems with administration and 
is a suggested scale for fatigue assessment by the Movement Disorders society task force for 
rating scales in Parkinson’s disease
Fatigue was additionally assessed while completing the detailed non-motor symptom scale 
(NMSS). The NMSS is the first composite non-motor scale, which was developed and validated 
to assess non-motor symptoms in PD over the last month. It is composed of 9 domains:
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Cardiovascular (2 items), Sleep/Fatigue (4 items), Mood/Apathy (6 items). Perceptual 
problems/Hallucinations (3 items), Attention/Memory (3 items). Gastrointestinal tract (3 items). 
Urinary (3 items). Sexual fimction (2 items), and Miscellaneous (4 items). Items are scored for 
severity (from 0 to 3) and frequency (from 1 to 4), to capture symptoms that are severe but 
relatively infrequent or that are less severe but persistent. The theoretical maximum total score is 
360. Score for each item is based on a multiple of severity (from 0 to 3) and frequency scores 
(from 1 to 4) (figure 4). The scale can therefore capture symptoms that are severe but relatively 
infrequent (e.g. hallucinations) and those that may be less severe but persistent (e.g., 
constipation, fatigue or low mood). This method increases the weight of symptoms that 
simultaneously are persistent and severe.
Two large international studies have confirmed the reliability and reproducibility of the NMSS 
and the individual domains and items In the most recent validation study of NMSS, 411 
PD patients with 61.3% being men were recruited from an South American, USA, European and 
Asian population base^^^l The mean age of this cohort was 64.5±9.9 years with disease duration 
of 8.1±5.7 years and the mean NMSS score was 57.1±44.0 In relation to clinimetric issues, 
the scale was free of floor or ceiling effects while skewness was 1.2. The scale has 9 domains 
and for domains, Cronbach’s alpha coefficient ranged from 0.44 to 0.85 which was very 
acceptable. Interclass correlation coefficient for the total score was 0.90 (for domains, 0.67-0.91) 
and Lin’s concordance coefficient, 0.88. NMSS total score correlated significantly with 
concurrent measures of autonomic dysfunction (SCOPA-Autonomic) and health related quality 
of life (PDQ-39 and EQ-5D (rs=0.57-0.70)). Association was close between NMSS domains and 
the related SCOPA-Autonomic domains (rs=0.51-0.65), and also with several other scales which 
has been developed to measure related constructs such as the PD sleep scale, SCOPA
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psychosocial (PDSS, SCOPA-PC) (all, p<0.0001). The standard error of the mean (SEM) was 
13.91 for total score and 1.71 to 4.73, for domains. The data indicated that in confirmation of the 
first validation study, the NMSS is an acceptable, reproducible, valid and precise assessment 
instrument for comprehensive and holistic assessment of NMS in PD including specific NMS 
such as fatigue and sleepiness. Two aspects of this study therefore, would address fatigue, the D- 
FIS measurements as well as the fatigue sub-item of the NMSS.
Assessments were usually performed in the “on” state for patients with motor fluctuations. In 
case patients were wearing off or troubled by the volume of questionnaires, I deferred the 
assessment to another day. All information was collated in a clinical research folder and stored 
for analysis. Patient identification was kept anonymous and numerical (Kings as K l, Lewisham 
as LI, etc.).
3.7. Other Assessments tools
UPDRS part 3: The UPDRS is globally used for assessment of motor and other aspects of PD 
and there is a new revised version available (MDS-UPDRS) which incorporates 13 aspects of 
non-motor issues in PD. However, the M D S -U P D R S h a s  not been widely validated for use yet 
and as such the older version of the UPDRS was used Part 3 specifically deals with motor 
aspects of PD to assess severity of motor symptoms of PD. The aspects addressed in part 3 
UPDRS include (speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, 
hand movements, rapid alternate movements, leg agility, arising from the chair, assessing posture 
etc.) and then scores are given on the basis of scoring from 0 (normal) to 4 (severe)
44
PDQ8: The PDQ8 is reliable, valid, responsive, acceptable and feasible as the tool for the 
assessment of HRQoL in PD. This scale has 8 items (assessing difficulty getting around in 
public, difficulty dressing, felt depressed, problems with close relationships, problems reading 
and concentrating on TV, books, communicate with people, painfiil muscle cramps and 
embarrassing in public due to their condition). Patients were asked to tick boxes indicating 
frequency (never, occasionally, sometimes, not at all)^^ l^ The PDQ-8 is derived and validated 
from the PDQ-39 questionnaire, a 39item questionnaire for HRQoL, which is grouped in 8 
domains on which PDQ-8 is based. Higher scores indicate poorer HRQoL.
HADS: The Hospital Anxiety and Depression Scale, HADS, is a self-administered instrument 
developed for detection of mood disorders in non-psychiatric outpatients attending hospital- 
consulting rooms. This is a questionnaire for assessing the symptom severity and caseness of 
anxiety disorders and depression in both somatic, psychiatric and primary care patients and even 
in the general population. The HADS contains 14 items and consists of two subscales: anxiety 
and depression. Each item is rated on a four-point scale, giving maximum scores of 21 for 
anxiety and depression. Scores of 11 or more on either subscale are considered to be a significant 
'case' of psychological morbidity, while scores of 8-10 represents 'borderline' and 0-7 
'normal'^^^ .^ The scale has been used and validated specifically for PD
3.8. Statistics
Descriptive statistics were used for the study variables as needed and in collaboration with the 
unit of Neuroepidemiology at the Carlos III institute in Madrid, Spain. For comparisons, the chi-
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squared, Mann-Whitney, or Kruskal-Wallis tests were applied, as the variables did not meet the 
assumptions for use of parametric statistics. The Benjamini-Hochberg method was applied in 
order to seek a balance between Error Types I and II and adjustment for multiple comparisons. 
An association was analysed by the Spearman rank correlation coefficient.
3.9. Results
A total of 135 patients had evaluable datasets and are reported in this study. Demographic details 
in relation to HY stages of patients included in the study are shown in table 9 while table 10 
relates the percentages of cases when classified to mild, moderate and severe disease based on 
HY stage grouping. Table 13 shows the distribution and range and scores of all the variables 
included in the study including the demographics. Mean fatigue VAS score was 62.52±19.9 in 
the sample. Table 11 indicates the fatigue scores stratified by disease severity and there was a 
significant correlation using the Kruskall-Wallis test. The details of anti-parkinsonian 
medications used in the sample are shown in Table 12. Dopamine agonists used in the study are 
grouped together and included patients on non-ergot and ergot agonists. Table 14 shows the 
breakdown of the non-motor scale data by domains and total score. Table 15 shows the 
correlations and significance levels between the fatigue scores on the VAS (D-FIS) scale and the 
different variables addressed in this study.
3.10. Discussion
This study was designed to address re-examination of the issue of addressing fatigue prevalence 
in a sample of PD patients across all stages of disease and examining its correlation with possible 
confounders/associates using validated scales and using the fatigue VAS (D-FIS) as the primary 
outcome variable. In spite of a number of studies the clinical correlates of fatigue remain poorly
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defined and we tried to address this in this study using a data driven approach. Our results 
support the common prevalence of fatigue in PD across all stages as has been reported in several 
studies.
The specific prevalence of fatigue in PD is poorly researched and an Italian study, the PRIAMO 
study showed that fatigue was present in patients presenting at HY stage 1 of the disease while 
the percentage of patients with fatigue rose as the disease progressed to stage 5 This 
suggests that fatigue can be present in early PD and even in untreated PD while some have 
suggested that fatigue could even be a pre-motor feature of PD^^l In the ELLDOPA study, 
patients were randomised to levodopa and placebo at an untreated stage and fatigue was also 
measured and Schifitto et al (2008) reported fatigue in 37% of untreated PD at baseline in non­
depressed PD patients Our study focused on patients from all stages in PD and 55.56% were 
from early PD cases, (Table 9) which also included untreated PD (mostly HY stage 1-1.5 cases. 
Table 10). The mean fatigue score in this group was 67.52±18.33 and less severe than fatigue in 
moderate (56.83±17.16) and severe cases (54.94±26.44) (Table 10) although there was a 
statistical significance of the difference (p=0.004). This emerged even though the representation 
of HY stage 5 cases in this study was relatively low as is to be expected in a study based on 
hospital outpatient assessment. The patient base used in this study was based on a “real life” 
population and broadly representative of the PD population as a whole with a mean age of 
69.7±10.52 years and an age range of 35 to 88 years. This is further emphasised by the fact that 
clinics at secondary and tertiary care centres as well as care of the elderly centres were also 
included. This suggests that fatigue occurs in early disease and in untreated PD cases, as well as 
in young and “old” PD cases as part of the disease process itself but the prevalence dose rise as 
the disease progresses as indeed indicated by other workers including the PRIAMO study. If  one
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therefore, considers the whole base of evidence underlying the issue of fatigue in Parkinson’s, 
the likelihood emerges that in a majority of PD patients, fatigue is intrinsic to the disease and can 
be present right at the onset of the motor syndrome.
Another aspect of this study set out to explore the variables that may affect assessment of fatigue 
and indeed could be regarded as “correlates” or “predictors” of fatigue using a data driven 
approach. In clinical practice, fatigue can be confused with excessive daytime sleepiness (EDS) 
as well as depression, apathy and general tiredness. The assessment of these confounders could 
be addressed in this study from scores of HADS (anxiety and depression), NMSS (sleep and 
EDS) and CIRS (tiredness). Our data, as tabulated by the summary of variables in Table 13 and 
Spearman rank correlation coefficient measures between the various variables and fatigue scores 
as shown in Table 15 indicate that the motor state and disease severity (UPDRS 3 and HY), 
anxiety and depression scores (HADS anx, HADS dep), mood, sleep from the NMSS scores, 
HRQoL as indicated by PDQ-8 assessments were the dominant variables to be associated with 
fatigue in PD (all p < 0.0001). This thus confounds the issue of “independent” fatigue in PD and 
concurs with the studies which have suggested that sleep disorders, depression and disease stage 
may be possible secondary causes of fatigue in individuals with PD However, we are also 
aware that several population-based studies in PD report that sleep disorders and in particular 
excessive daytime somnolence (EDS) do not account for fatigue in a majority of PD subjects. 
Hence further studies are required in patients who are selected for EDS and then specifically 
studied for fatigue using validated scales. Although there was a strong correlation our study also 
revealed cases that reported fatigue but did not have EDS. Further imaging studies in this cohort 
is reported in a following chapter.
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Depression and anxiety also emerged as strong predictors of fatigue in our study. This is not 
unusual and previously a long-term, nine-year follow-up study reported a correlation between 
measures of depression and fatigue Imaging studies using PET suggest that the limbic 
dopaminergic and noradrenergic areas may be involved in the pathogenesis of depression in PD. 
An in vivo imaging study using ^^C-RTI-32, a ligand which binds to dopamine and noradrenaline 
reuptake sites showed reduced binding in the locus coeruleus and the limbic system in depressed 
and anxious patients compared to non-depressed PD patients Pathophysiology of fatigue in 
PD is likely to involve the limbic pathways as well and is explored in an imaging study in this 
thesis. It is therefore, reasonable to conclude that fatigue and depression may be concurrent NMS 
of PD with considerable overlap. However, as with EDS, we also identified cases with 
depression and anxiety and no fatigue and vice versa and this illustrates the fact that both 
depression and fatigue are independent NMS of PD.
The CIRS is an instrument measuring the clinical burden of several medical problems in the 
same patient (multi-morbidity), in a family practice context and addresses the issue of alternative 
comorbidities that may influence fatigue as well as the concept of tiredness.^^^  ^ Both the sum 
score of CIRS as well as the summary score showed no significant relationship with fatigue in 
this cohort (Table 15). Once again this data emphasises fatigue as an independent NMS of PD 
and one that is not necessarily linked to aspects of general physical illness.
The wide range of cases in the study allowed us to address fatigue in different subtypes of PD 
although this study was not powered to address fatigue and clinical phenotypic differences 
within PD and furthermore, many authorities do not accept these subtyping of PD (table 8). We 
found no difference in fatigue scores between sub-types of Parkinson’s and akinesia-dominant
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cases had similar levels of fatigue compared to tremor-dominant types and fatigue levels were 
also similar between male and female patients. Correlation with disease severity was then 
addressed by subdividing the observed cases to mild, moderate and severe disease as indicated 
in. Using the Kruskall-Wallis comparative measures. Fatigue levels were seen to worsen as the 
disease became severe when measured by the HY stage and graded as mild, moderate, and 
severe (Table 10). This observation is in line with the recently reported PRIAMO study where 
fatigue levels were reported incrementally as HY stages increased
The confounding aspect of effect of medication on fatigue has been poorly studied and the data 
are scarce and can be contradictory. In a survey of fatigue and different dopaminergic 
medications, Hoff et al concluded that there was no evidence of any dopamine agonist effect on 
fatigue in PD. Our study was not powered or indeed set up to distinguish between effect of 
medications and fatigue. However, the level of fatigue between drug-naive cases and those 
treated with either mono or combination therapy of anti-parkinsonian agents were similar and 
provided indirect support for the observation that fatigue in Parkinson’s appeared to be 
unaffected by conventional PD therapy (Table 12). However, we observed a trend (although non­
significant) of better fatigue scores in those treated by combined L-dopa and dopamine agonists 
(fatigue score of 71.3±19.1 in untreated PD vs 60.6±20.6 in combined therapy). At least one 
study has suggested that pergolide, an ergot dopamine agonist may improve fatigue in PD 
although controlled studies are lacking Further studies with head to head comparisons may 
address this issue further as at the moment the only randomised controlled study of therapy for 
fatigue involves the non dopaminergic medication methtylphenidate as reported in the task force 
document of the American Academy of Neurology on evidence based treatment for NMS of 
pj^ [67-68] purthermore, a recent randomised double blind placebo controlled study of rotigotine
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patch, a transdermal non-ergot dopamine agonist, the RECOVER study has also reported 
improvement in fatigue with the patch and not placebo
Table 13 further explores the mean, standard deviation and range values of all the observed 
variables in this study while table 14 describes similar values for all the domains studies by the 
NMSS including fatigue, NMS-Quest as well as total NMSS scores. When the NMSS scores are 
considered ion this study cohort, mean fatigue and sleep domain scores showed the highest 
disability (11.11±9.03, range (0-48) amongst all the other NMS domains apart from mood 
(10.56±14.34, Table 14). Taken together this data from the NMSS are confirmatory of the 
overall observation as shown in the correlation analysis that sleep dysfunction (in particular EDS 
and mood problems (anxiety and depression) are the strongest associates of fatigue in this cohort.
3.11. Conclusions
This large “real life” outpatient cohort based, one point in time study addressing various NMS of 
PD with a focus on fatigue, using validated measures suggest that fatigue is present in PD as a 
dominant symptom across all stages of PD although the severity tends to increase with advancing 
disease. Fatigue tends to occur independent of gender differences, disease duration and also 
postulated subtypes within PD such as tremor dominant versus akinesia dominant cases although 
the latter concept remains controversial. Depression, anxiety and sleep problems such as EDS 
appear to be the strongest predictor or associates of fatigue in PD although these can exist 
independently and further large scale studies are required to unravel the contributions of aspects 
of each of these NMS. This was our a priori hypothesis and may support a view held by 
Shulman et al (2001)^ ^^^  who suggested that non-motor symptoms of PD such as fatigue, 
depression, and pain could share the same pathogenic origins. Our study shows a consistent
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association of fatigue with some other aspects of NMS as measured by the NMSS and thus is 
consistent with the above-mentioned hypothesis. Less robust association was observed for 
instance with cardiovascular NMS such as orthostatic tolerance, sexual function, pain, 
hyperhidrosis, attention, and memory functions. A strong correlation of HRQoL with fatigue is 
also reported as indeed observed previously by many authors. Fatigue tends to occur independent 
of dopaminergic drug therapy although there appears to be a “signal” suggesting dopaminergic 
therapies may be beneficial although our study was not powered or aimed to address drug effects 
on fatigue.
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Table 8: The subtype of PD studied in this sample. l=Trem or; 2=Akinetic; 3=Mixed
Frequency Percent (%)
Tremor dominant 33 
Akinesia dominant 39 
Mixed 63
24.44
2&89
46.67
Table 9: Distribution of disease severity as measured by HY stage
H&Y Severity Frequency Percent (%)
1 16 11.85
1.5 17 12.59
2 22 16.30
2.5 20 14.81
3 42 31.11
4 15 11.11
5 3 2.22
Table 10: Distribution of patients by HY stage severity
H&Y Severity Frequency Percent (%)
Mild (1-2.5) 75 55.56
Moderate (3) 42 31.11
Severe (4-5) 18 13.33
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Table 11: Mean and standard deviation of fatigue scores by HY staging severity
H&Y Severity Mean SD* Kruskall-Wallis Test p-value
Mild (1-2.5) 67.52 18.33 0.004
Moderate (3) 5&83 17.16
Severe (4-5) 54.94 26.44
SD = standard deviation
Table 12: The distribution of anti-Parkinsonian therapy in the study patients
Therapies Frequency Percent (%)
Drug naive 12 &89
Levodopa mono-therapy 50 37.04
DA mono therapy 11 8.15
Levodopa + DA* 61 45J9
Others 1 0.74
DA = Dopamine agonists
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Table 13: Study summary measures
Variable N Mean SD* Minimum Maximum
Age 135 69.74 10.52 25 88
Duration 135 5J8 5.19 0 32
Age at 
diagnosis
135 63.88 11.34 29 65
Updrs 3 130 16.13 8.01 2 44
Updrs 4 132 2.92 3.03 0 13
Dyskinesia and 
Fluctuation
132 2 J2 2.74 0 12
Upd4_oth 132 0.60 0.67 0 3
Cumulative 
illness rating 
scale
135 4.74 2.84 0 15
Cumulative 
illness rating 
scale SI
131 1.91 0.61 1 3.5
fatigvas 135 62.52 19.90 10 100
HADS Anxiety 
subscale
135 10.73 4.79 0 21
HADS
Depression
135 10.19 4.62 1 21
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subscale
Frontal 134 14.79 2 j3 3 18
assessment
battery -T
PDQ-8 134 2&19 17.82 0 78.13
Table 14: Non-motor scale data distributions
Variable N Mean Standard Minimum Maximum
Deviation
NMSQTot 129 10.11 4.95 0 24
Gastrointestinal 135 4.38 5.14 0 23
Urinary 135 6.44 7.01 0 36
Cardiovascular 133 2.60 4.04 0 21
Sexual 135 3.08 5.66 0 24
Function
Sleep/Fatigue 135 11.11 9.03 0 48
Perceptual 135 1.81 4.43 0 36
problems
Mood 135 10.56 14.34 0 72
Attention and 135 5.97 8.03 0 36
Memory
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Miscellaneous 135 
Total score on 133 
NMSS
6.66
52.96
7.38
41.52
36
243
Table 15: Spearman rank correlations between the various variables and fatigue scores.
Variable Correlation (r) p-value
Age N.S.
Updrs 3 -&2380 0.0064
Updrs 4 -0.1968 0.0237
CI RSs um N.S.
C I RS S I N.S.
Hads anx -0.3948 <0.0001
Hadsdep -0.4171 <0.0001
F A B T 0.3374 0.0001
N MSOt o t -0.3122 0.0003
Sleep Domain Quest -&2823 0.0009
Other NMSQuest domains N.S.
HY -0.2882 =0.0007
PDQ_8 -0.367 <0.0001
NMSS_Tot3 -0.3924 <0.0001
Cardiovascular -0.2985 0.0004
Sexual function -0.2576 0.003
Sleep -0.3908 <0.0001
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Mood -0.3766 <0.0001
Attention/Memory -0.2574 0.003
Miscellaneous -0.2666 0.002
Other NMS Scale domains N.S.
*NS = not significant
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Figure 4: Non-motor symptom assessment scale (NMSS) for Parkinson’s Disease
Non-Motor Symptom assessment scale for Parkinson’s Disease
P a tie n t ID  N o: Initials: Age:_
SjTiiptomji assessed over the last monîti. llach s jiiip to m  scored with respect to;
Severity: 0  =  N one, 1 =  M ild; sym ptom s present t u l  causes little distress or disturbance to  patient; 2 = M oderate: som e distress 
ordisnirhiiBrff topatii-nt; !t -  S evirc- m ajor snuroo o f  distress nr distirrhaiico to  patient
Frequency: 1 =  K arciy (<1 AvkJ; 2  =  O lten  ( l/w k ); 3 =  Frequent (several times per w eek); 4  =  V ciy  Frequent (daily o r all Itic tim e)
D om ains w ill be w eighed d ifferentially . Y e s ' No answ ers ate not included in  final fiequcncy x severity  calculation. 
(Bracketed tex t in  questions w itliin llie scale is included as an explanatory aid).
D o m ain  1: C a rd io v a s c u la r  In c lu d in g  fa lls
1. Docs the patient experience ligtil-hcadcdncss, dizziness, weakness on standing from sitting 
or lying position?
2 . D o c s  the p a tie n t  fa ll b e c a u s e  o f  fa in tin g  o r  b la c k in g  o u t?
S C O R E :
S ev e rity  r re q u e n c v  
□ □
Frequcney 
I  Scvcrilv
□ □ □
D o m ain  2 : S leep /fa tig u e
3. Docs the patient doze o f!'or fall asleep unintentionally during daytime activities?
(For example, during conversation, during mealtimes, or while watching television or reding).
4 . D o c s  fa tig u e  ( tire d n e s s )  o r  la c k  o f  e n e rg y  (n o t s lo w n e s s )  lim it  ih c  p a t ie n t 's  d a y t im e  a c t iv i t ie s ?  
S D o c x  th e  pH trrnt h a v e  H iff îr jillics  fa llin g  n r  s t .iy in g o s l re p ?
6. Does the patient experience an urge to move (he legs o r restlessness in legs that improves with 
movement when he/she is sitting or lying down inactive?
.SCO R E:
D o m ain  3 : M o o d  /C o g n itio n
7. Has the patient lost interest in his.dier surroundings?
8. Has the patient lost interest in doing things or lack motivation to start new activities?
9 . D o c s  th e  p a tie n t  feel n e r v o u s ,  w o r r ie d  o r  fr ig h te n e d  f o r  n o  e p p a rc n t r e a s o n ?
10. Does the patient seem sad or depressed or has he/she reported such feelings?
11. D o c s  th e  p a t ie n t  h a v e  f la t m o o d s  w ith o u t th e  n o rm a l " h ig h s "  a n d  “  lo w s” ?
12. Does the patient have difficulty in experiencing pleasure from their usual 
activities or report that they lack pleasure?
S C O R E :
D o m ain  4 : P e rc e p tu a l  p ro b le m s/h a llu c in a tio n s
13. Docs the patient indicate that he/she sees things that arc not there?
14. Docs ttic patient have liclicfs that you know ate not liuc? (Foi example, 
about being harmed, being robbed or being unfaithful)
15. Docs the patient experience double vision?
(2 separate real objects and not blurred vision)
S C O R E :
□ □ □
□ □ □
□ □
□ □ □
1 = ]
□ □ □
□ □ □
□ □ □
□ □ □
□ □ □
□ □ □
IZZI
□ □ □
□ □ □
□ □ □
IZZI
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ScYfrity Fryqiicpcy Freqiicncv
Domain 5: A ttention/ M em ory
16. Docs the patient have problems sustaining concentration during activities? 
(For example, reading or having a conversation) □ □ □
17. Does the patient forget things that he,'she has been told a short tim e ago or 
events that happened in the last few days?
□ □ □
18. Docs the patient forget to do thing.s?
(For example, take tablets or turn o ff domestic appliances?) 
SCO RE:
Domain 6: G astro in testina l tra c t
□ □ □
c z
19. Does the patient dribble saliva during tlic day? □ □ □
20. Docs the patient having difficulty swallowing?
21. Docs the patient suffer from constipation?
□ □ □
(Bowel action less tlian three times weekly) 
SCORE:
□ □ □
IZZI
Domain 7: U rinary
22. Does the patient have difficulty holding urine? (Urgency)
23. Does the patient have to void within 2 hours o fla st voiding? (Frequency)
24. Docs the patient have to get up regularly at night to pass urine? (Nocturia) 
SCORE:
Domain 8: Sexual function
25. Does the patient have altered interest in sex?
(\'cr)' much increased or decreased, please imdcrlinc)
26. Does the patient have problems having sex?
SCORE:
D om ain  9 : M isce llan eo u s
27. Docs the patient suffer from pain not explained by other known condition!:? 
(Is it related to intake o f drugs and is it relieved by antiparkinson drugs?)
28. Does the patient report a change in ability to taste or smell?
29. Does the patient report a recent change in weight (not related to dieting)?
30. Docs the patient experience excessive sweating? (not related to hot weather) 
SCORE:
□ □ □
□ □ □
□ □ □
IZZI
□ □ □
□ □ □
IZZI
□ □ □
□ □ □
□ □ □
□ □ □
IZZI
TmAi.srnRF,
Developed by the International Parkinson’s Disease Non- M otor Group.
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CHAPTER 4
FATIGUE IN PARKINSON’S DISEASE: EXPLORING PERIPHERAL AUTONOMIC 
DYSFUNCTION AS A PATHO-LHYSIOLOGICAL MECHANISM USING CARDIAC 
META-IODOBENZYLGUANIDINE (MIBG) SCANS
Related papers:
I. Metta V, Corcoran B, Buxton-Thomas M, Gage H, Naidu Y, Martinez-Martin P, 
Chaudhuri KR. Fatigue in Parkinson’s disease: clinical aspects and exploring peripheral 
autonomic dysfunction as mechanism using cardiac MIBG scans. Presented to the 
, International Society of Movement Diorders Annual Meeting. Paris. June 2009. Mov 
Disord 2009; 24(supplement SI):We 371. S 531
II. V Metta, K Logishetty, P. Martinez-Martin, Heather M. Gage, P.E.S. Schartau, T.K 
Kaluarachchi, Anne Martin, Per Odin, P. Barone, Fabrizio Stocchi, A. Antonini, K Ray 
Chaudhuri The possible clinical predictors of fatigue in Parkinson’s disease: a study of 
135 patients as part of international non motor scale validation project. Parkinson’s 
Disease 2011’. Volume 2011, Article ID 125271,1-7. doi: 10.4061/2011/125271
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4.1. Introduction
In the previous chapters we have argued for the evidence that fatigue is a key non-motor 
symptom (NMS) of Parkinson’s disease (PD) and can occur independently of depression and 
daytime sleepiness. However, the data presented and published from the work outlined in 
Chapter 3 also suggests that depression and anxiety along with sleep disorders such as excessive 
daytime sleepiness (EDS) strongly influence fatigue in PD Studies such as the PRIAMO and 
those related to non motor symptoms scale have also shown the high prevalence of fatigue in any 
given population base of PD, the latter study by Martinez-Martin in 2009 reporting that out of 
411 patients with PD completing the NMSS, fatigue as rated by the NMSS was reported in 
65.9% of PD patients and was shown to be the second most frequent NMS (after nocturia which 
was reported by 68.4% of PD patients) and was closely associated with negative measures of 
health related quality of life (HRQoL).^^^’
Although the patho-physiological mechanisms underlying fatigue in PD are not fully understood, 
studies in patients with morbidities such as depression, osteoarthritis and diabetes have suggested 
that fatigue is associated specifically with PD and not general motor impairment However, 
as the previous study reported in Chapter 3 indicates that when diagnosed, fatigue is often 
associated with the co-occurrence of other NMS, particularly depression and sleep disturbance. 
In the study reported in Chapter 3, cardiovascular morbidity in the observed sample was low 
(2.66±4.04. see Table 14 of Chapter 3) compared to other NMS such as sleep and fatigue and 
mood problems. However, Spearman correlation coefficient of cardiovascular domain with 
fatigue was significant with R = -0.2985 and a p value of 0.0004 (see Table 15 of Chapter 3). 
The autonomic nervous system (ANS) which regulates the cardiovascular system is known to be
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affected early in Parkinson’s and the Braak hypothesis would suggest that autonomic dysfunction 
mediated through the brainstem medullary centres may even arise in the pre-motor stage of 
Parkinson’s Peripheral and central autonomic structures may be involved and neuropathology 
shows Lewy bodies in both peripheral and central autonomic structures in PDJ^^  ^ Since the 
1980’s there have been growing evidence that peripheral autonomic nerves are abnormal in PD 
and that this could explain the occurrence of orthostatic hypotension and other autonomic 
abnormalities in PD. Typical Lewy body inclusions, containing a-synuclein, have been reported 
in autopsy proven cases in the peripheral autonomic neurons of patients with classical idiopathic 
PD.^ ^^  ^ In these cases, there was widespread eosinophilic ubiquitin and a-synuclein-positive 
Lewy bodies in the ganglion cells and axons of the paravertebral and prevertebral mesenteric 
sympathetic chain, stellate ganglia and cardiac plexus.^^^  ^The consequence of this pathological 
abnormality is likely to be a secondary loss of sympathetic neurons innervating the peripheral 
vasculature and in particular, the heart of patients with PD. In vivo imaging of the heart is now 
possible and studies over the last decade have shown that patients with PD frequently have 
impairment or in some cases complete loss of sympathetic innervations of the heart Goldstein 
and colleagues have also recently highlighted the issue of cardiac sympathetic denervation in PD 
as a pre-motor feature and have drawn attention to the fact that there may be differential 
autonomic involvement in PD with cardiac autonomic denervation being the earliest and 
correlating with the Braak theory of pre-motor stage of PD.^ ^^  ^ The following Figure (below) 
taken from his article shows the absent image of heart in an asymptomatic individual (indicating 
intact cardiac sympathetic function) being visible (evidence of early cardiac denervation) over a 
period of 4.5 years when the subject develops signs of PD.
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Figure 5: Pre-motor and cardiac sympathetic denervation at diagnosis of a case of PD [75]
1®FDA 1®FDA 1®NH:
First evai.
4.5 years
Autonomic disturbances are thought to account for a range of NMS of PD and fatigue has been 
suggested as a possible effect.^ ^^  Braak et al. have popularised and developed the theory that a six 
stage pathological process underlies the pathogenesis of PD.^ ^^  This begins at induction sites with 
degeneration of the olfactory bulb and the anterior olfactory nucleus (clinically manifested as 
olfactory dysfunction) at stage 1. Stage 2 reflects progression of the pathological process to the 
lower brainstem and the latter involves brainstem nuclei, which are thought to be key areas 
which mediate NMS such as central autonomic control and also one that controls the outflow of 
sympathetic influence to the heart and possibly have a role in the symptom of fatigue. It is 
therefore possible to explore a possible peripheral autonomic patho-physiological basis of fatigue 
in PD by undertaking cardiac autonomic investigations in PD.
64
4.2. Cardiac MIBG scanning and PD
Decreased cardiac uptake of meta-iodobenzylguanidine (MIBG), a physiological analog of 
norepinephrine, on ^^^I-MIBG myocardial scintigraphy, or of fluorodopamine on 6-[18F] 
fluorodopamine positron emission tomography has been reported in patients with Parkinson's 
disease (PD) and dementia with Lewy bodies (DLB)^ "^^ ’ These studies are based on the
hypothesis that impaired catecholamine uptake by postganglionic sympathetic neurons 
innervating the heart canm be demonstrated by low myocardial concentrations of radioactivity 
after injection of sympathoneural imaging agents such as ^^^I-metaiodobenzylguanidine (MIBG), 
6-[^^F] fluorodopamine and ^'C-meta-hydroxyephedrine^^"^’ Post-mortem pathologic studies
confirm the imaging abnormalities showing attenuation of tyrosine hydroxylase immune-reactive 
axons in the left ventricular anterior wall of the heart of patients with PDJ^^  ^ Many have 
proposed that cardiac MIBG scans which are often routinely undertaken in NHS hospitals to 
investigate cardiac disorders could be used to investigate parkinsonian autonomic dysfunction. 
Cardiac uptake of MIBG is decreased even in the early stages of PD (Hoehn-Yahr stage 1 or 2), 
which suggests early involvement of the cardiac sympathetic nerve, even though at this stage, 
routine autonomic function tests may fail to detect autonomic dysfunction. Our a priori 
hypothesis was therefore, that fatigue as measured by one of the validated fatigue scales may 
show a correlation with cardiac MIBG uptake and be present in those with cardiac sympathetic 
denervation which may act as a marker of dysautonomia in PD and that this feature may be 
evident in early PD. In confirmation of our hypothesis, a recent study using ^^ I^- 
metaiodobenzylguanidine scans in PD has shown a significant correlation between Parkinson’s 
fatigue scale and cardiac *^^I-metaiodobenzylguanidine (MIBG) u p t a k e . I n  this study we have
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tried to address the above hypothesis by using cardiac MIBG scans in a group of PD patients 
with fatigue compared to a group without.
4.3. Methods
Patients were recruited at King’s and Lewisham Hospitals regional PD clinics as part of routine 
clinical motor and non-motor screening and as part of study reported in Chapter 3. Those who 
were identified to be fatigued as part of the non motor protocol as described in Chapter 3 were 
further screened using the Parkinson’s fatigue scale 16 (PFS-16) as described by Brown et al and 
one that is recommended for use by the Movement Disorders Society task force. The task 
force recommendations were published following the work described in chapter 3 and as such we 
decided to use PFS-16 in this arm of the work.
We selected 25 patients from the previous study who had reported significant fatigue on use of 
the fatigue VAS (D-FIS) and 25 matched patients who did not complain of fatigue on VAS as 
described in Chapter 3. To these patients PFS-16 was applied additionally and patients with 
significant fatigue on PFS-16 were selected and compared to those without for this pilot 
exploratory study. In this study, we also excluded patients with significant depression (Hamilton 
Rating Scale for Depression (scores > 13)) or sleep disturbances according to the Parkinson’s 
Disease Sleep Scale (PDSS Validated for sleep disorders in PD, scores < 100).
The tool specific to this report is the PFS-16, a self-report scale composed of 16 items which is 
used to assess the physical aspects of fatigue in PD and their bearing on quality of life (QoL).^ '^ ^^  
The binary score for each item was selected for the present study as recommended by Brown 
who developed of the scale. The scale has good clinimetrics and cut off scores for the presence
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or absence of fatigue in PD, and have shown good sensitivity and spec i f i c i t y .PFS 16 was 
developed for clinical use and for use in research to screen as well as to evaluate fatigue severity. 
The scale contains seven items that address the presence or absence of the subjective experience 
of fatigue, with a specific emphasis on the physical consequence of fatigue, such as, “ I feel 
totally drained.”  There are additional nine items that reports the impact of fatigue on activities of 
daily living such as socialization and work, but not specifically including exercise. An example 
would be the question “ I get more tired than other people I know.” The scale dose not 
specifically measure severity or frequency of fatigue symptoms. The ratings in the scale are 
based on feelings and experiences of the patient over the prior 2 weeks. Some items assessing the 
impact of fatigue does overlap with aspects of mood disturbances. The scale has good 
clinimetrics and the item response options range from 1 (“ strongly disagree” ) to 5 (“ strongly 
agree” ). A total PFS score, the average item score across all 16 items, ranges from 1 to 5. A 
binary scoring method yields scores from 0 to 16, with positive scores for each item generated by 
“ agree” and “ strongly agree” responses. A third option, used in the subsequent study, 
calculates a total PFS score (range 16-80) based on the sum of scores for the 16 individual items. 
The scale has good data quality and reliability (Cronbach’s a 5 0.97-0.98; test-retest 5 0.82 
using the total score and 0.82 formhe binary scoring method). Internal validity of the scale was 
adequate to high. Split-half analysis showing correlations 0.93 to 0.95 and internal consistencies 
of 0.90 to 0.97.
In the final analysis we were able to image 20 patients (10 with PFS-16 score > 8 (identified as 
“fatigue positive”) and 10 fatigue negative (PFS-16 score < 8). All patients first underwent 2- 
methoxy isobutyl isonitrile (MIBI)) scintigraphy to ensure intact myocardial perfusion as this 
ligand reflects cardiac blood flow. Prior to MIBI scanning, intravenous injection of dipyridamol
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(0.65mg/kg) was given as per routine protocol at the nuclear imaging department at Kings 
College Hospital. Scanning with MIBG was only undertaken if the MIBI scan was reported as 
within normal limits. All patients with normal MIBI scan underwent *^^MIBG scintigraphy under 
thyroid blockade with oral administration of 150 mg of potassium iodide as per routine practice. 
Regional ^^^MIBG uptake was assessed using two SPECT (single photon emission tomogram) 
cameras.
Projection imaging were taken for 15 mins and after 3 hrs following injection of ^^^MIBG. The 
nuclear imaging department at Kings College Hospital had devised qualitative assessment using 
uptake ratios of ^^^MIBG. Cardiac MIBG uptake was assessed qualitatively (heart visualisation 
score ranging from 0- 1.5 (0 = no heart visualisation, 1 -  faint cardiac uptake and 1.5 + Heart 
clearly visible). For this purpose rectangular region of interest (ROI) OF 4 x 4 pixels were 
drawn on the heart, the mediastinum and liver for each planar images. MIBG myocardial uptake 
was assessed using heart to mediastinum activity ratio taking the average count per pixel in the 
ROI. Cardiac MIBG uptake was analysed using a standard protocol using uptake values at 15 
min (Rl) and 3 hrs (R2) in addition to cardiac MIBI scans to exclude any perfusion defects (Figs 
6a and 6b). MIBG uptake reflects specific binding to noradrenaline transporters and as such is a 
reasonably sensitive indicator of cardiac sympathetic integrity. The cardiac uptake ratios 
therefore, reflects an indirect measure of cardiac autonomic integrity and in this study was 
thereafter correlated to fatigue state to explore whether dysautonomia and fatigue may be related 
in PD. As per local laboratory values, a ratio of R1:R2 of 1.5 or less was regarded as low uptake 
of MIBG and 1.5 was taken as the cut off value.
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Fig 6A: The early uptake MIBG image (R l) at 15 min with visualization of the heart 
(arrow). Courtesy Nuclear Imaging Department of Kings College Hospital (Dr M Buxton- 
Thomas and Nicola Mullholand)
Fig 6B: The late uptake MIBG image (R2) at 180 min with visualization of the heart 
(arrow). Courtesy Nuclear Imaging Department of Kings College Hospital (Dr M Buxton- 
Thomas and Dr Nicolla Mullholland)
4.4. Results
The mean age of the sample was 67.33±8.65 (range 49 — 78 yrs). This included fatigue positive 
cases as based on PFS-16 cut off (mean fatigue score 11.9 ± 1.44) and fatigue negative cases (5.5
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± 1.4). All had normal MIBI scan analysis and subsequently underwent MIBG scanning as 
above. The Rl and R2 uptake scores in the fatigue positive vs negative groups are shown in 
Table 16 and were not significantly different.
Table 16. R l and R2 uptake scores in the fatigue positive vs negative groups
MIBG uptake Fatigue Positive Fatigue Negative Significance
N=10 N=10
[ R l uptake 1.6 ±0.53 1.5 ±1.37 NS*
R2 uptake 1.58 ±0.48 1.48 ±0.23 NS*
*NS = non-significant
Figure 7 (below) shows a patient with PD but no fatigue and there is visualization of the heart in 
the top panel as is expected with MIBI imaging suggesting normal cardiac blood flow. However, 
MIBG imaging at Rl (15mins) and R2 (3hrs) shows no visualization of the heart as is usual in 
PD. However, this was a patient with no fatigue and as per our a priori hypothesis, we should not 
have seen cardiac denervation and as such expected to see normal visualization of heart.
Figure 7: MIBI and MIBG images from a PD patient with no fatigue showing cardiac 
sympathetic denervation on MIBG imaging (lower panels)
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We also conducted a correlation analysis using Spearman rank correlation between Rl and R2 
uptake values with differences between Rl and R2, mean age of the sample, PFS-16 scores, 
motor subsection of the unified Parkinson’s disease rating scale, NMSS and quality of life as 
measured by PDQ-8 (Table 17). No significant correlation was observed in particular with PFS 
16.
Table 17: Spearman rank correlation coefficient values for R l and R2 MIBG uptake values 
with concomitant measures of age of sample, duration of PD, Unified Parkinson’s disease 
rating scale, subsection 3 (UPPDRS-3), non-motor symptoms scale (NMSS) and 
Parkinson’s disease quality of life summary index (PDQ8 SI) in 20 cases. (obs=21). All 
values are not significant (NS).
Variables R l MIBG uptake R2 MIBG uptake Significance
(Age -0.602 -0.5231 NS
Duration of PD 0.1569 0.1812 NS
1 PFS-16 -0.0460 0.0379 NS
UPDRS 3 0.0654 0.0166 NS
|NMSS -0.2917 -0.2246 NS
PDQ8 SI 0.1091 0.0656 NS
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4.5. Discussion
As discussed previously, this was a small pilot exploratory study and as such power calculation 
was not possible. We are not aware any other work on this subject apart from a very recent study 
from Japan by Nakamura and colleagues which will be discussed later. We based this small 
study on a priori presumption and hypothesised that if fatigue is mediated through the autonomic 
regulatory pathways and dominantly via the sympathetic regulatory system then cardiac MIBG 
uptake would provide a sensitive way of picking up this abnormality as the heart is one of the 
most intensely innervated organs. The assumption was that MIBG uptake is likely to be reduced 
in the PD patients with significant fatigue as indicated by abnormal PFS-16 scores using the 
established cutoff values. From the sample of patient’s studies in chapter 3 we were also able to 
include a subgroup of patients who showed no fatigue based initially on D-FIS assessment and 
thereafter with PFS-16. These patients underwent clinically indicated MIBG scans and the data 
was used to compare with the group that had fatigue.
As described previously MIBG was chosen as a marker of cardiac sympathetic integrity based on 
the literature supporting the notion that MIBG uptake maybe more sensitive than other measures 
of autonomic ftmction in detecting early a b n o r m a l i t i e s . N o t  only studies have consistently 
showed abnormal pattern of MIBG uptake across all stages of PD but autopsy studies have 
confirmed presence of Lewy bodies in cardiac sympathetic neurons.
We could only study a small number of patients in each group owing to logistical difficulties 
with the scanning (in several patients scans failed as well as artifacts were introduced owing to 
head movement in disabled PD patients). The data therefore is by no means confirmatory. We
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chose 25 patients in each group for this reason and satisfactory scan data could only be obtained 
in 10 of each group. Attrition was also due to the fact that many patients were unable to tolerate 
the rigors of having to travel to the Hospital from afar and undergo two spate time-consuming
scans.
All patients who were classed as fatigue positive were recruited from the previous study and who 
had rated fatigue as a prevalent symptom in the D-FIS scale. PFS-16 was then applied and 
fatigue was once again confirmed on this scale. These patients underwent MIBI scanning to rule 
out in any cardiac vascular defects, which may cloud and confound MIBG uptake measure 
indices (Fig 7). So as not to miss delayed uptake abnormalities, uptake values were recorded at 
15 min (Rl) as well 180 min (R2) (Figs 6a and 6b). Extensive experience in MIBG scanning in 
patients with PD had earlier established cutoff normal and abnormal uptake ratios at the imaging 
centre. These were a value of 1.5 (above 2 being typical of normal uptake). Patients were studied 
under uniform conditions and in an "on" state as “ o ff’ period scanning is difficult and 
distressing to patients. As is clear in Table 16, that there were no differences in Rl and R2 
uptake values between fatigue positive and negative cases. This suggest that our a priori 
hypothesis could not be proven in this pilot exploratory study and that cardiac denervation 
cannot be attributed to be the cause of fatigue at least in this sample of patients.
Nakamura and colleagues studied 33 patients with cardiac MIBG scans based on positive fatigue 
(n=12) and no fatigue (n=21) using the PFS-16 similar to ours. They also conducted autonomic 
cardiovascular tests such as coefficient of variation of R-R intervals and head up tilt tests, which 
showed no differences between the fatigue positive versus the fatigue negative g r o u p . T h e i r  
data however, indicated that the ^^^MIBG heart-to-mediastinal uptake ratio was lower in the
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fatigued group than in the non-fatigued group which was our original a priori hypothesis (Fig 8). 
Partial correlation analysis was also conducted, using disease duration and HY stage as control 
variables, also demonstrated significant correlations between the Parkinson fatigue scale score 
and the results of the autonomic function tests and cardiac ^^^I-metaiodobenzylguanidine uptake. 
This apparent anomaly between the results of Nakamura et al and ourselves could be explained 
partially by the small sample size of our cohort but also by the fact that the fatigued patients in 
the Nakamura study had a higher UPDRS 3 score (although non significant) compared to the non 
fatigued group (27.3(11.7) vs 18.4(13.1)) and our patients who were generally in an earlier 
Hoehn and Yahr stage. Furthermore, the MIBG heart to mediastinum ratios (early and late) 
showed considerable overlap between fatigues and non-fatigue patients in the study by 
Nakamura et al (Fig 8, panels E and F) even in a relatively small sample studied. The results of 
these exploratory study therefore, clearly indicates that further studies in this field needs to be 
undertaken and cardiac MIBG scanning may yet emerge as a useful marker for identifying 
fatigue in PD patients.
We also carried out correlation analysis with other variable as indicated in Table 17. We found 
no correlation of fatigue with disease duration of PD as well as age of patients in addition to the 
motor state (UPDRS 3) similar to the observations of Nakamura et al. In addition we observed 
no correlation in this small study with the total NMSS and quality of life (PDQ8 SI). However, 
as outlined above the data is limited by a small sample size and exploratory nature of the study 
and thus wider extrapolation is difficult and somewhat contradictory as shown by the Nakamura 
study^ ^^ .^ The key observation from this study therefore suggests, that although abnormal cardiac 
sympathetic innervation may be a marker of fatigue in a subset of PD, this requires a much larger 
study cohort to be confirmatory. Our study has failed to show any evidence of cardiac defect in
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fatigued PD while one other study in a small ample of patients has suggested a cardiac 
sympathetic defect but large-scale further studies using cardiac MIBG scanning as a surrogate 
marker of sympathetic dysfunction needs to be undertaken.
Fig 8: Data shown from the paper of Nakamura et al indicating a lower cardiac MIBG 
uptake and aspects of cardiovascular autonomic function tests in patients with fatigue 
compared to those without
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CHAPTER 5
Pathophysiological basis of fatigue in Parkinson’s disease: a positron emission tomography 
study addressing central dopaminergic and serotonergic mechanisms
Related papers/abstracts:
I. Pavese N, Metta V Bose SK, Chaudhuri KR, Brooks DJ. Fatigue in Parkinson's disease is 
associated to reduced brain serotonin and dopamine innervation. Neurol 2010;74 (9 
Suppl2): A298-299.
II. Pavese N; Metta V; Bose SK; Chaudhuri KR; Brooks DJ. Fatigue in Parkinson's disease 
is linked to striatal and limbic serotonergic dysfunction. Brain 2010; 133:3434-3443.
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Abstract
Objective: Disabling fatigue is common in Parkinson’s disease (PD) and has a significant 
negative impact on patients’ quality of life. We used 18F-dopa PET, a marker of dopamine 
terminal function, and IIC-DASB PET, a marker of serotonin transporter (SERT) 
availability, to investigate whether fatigue in PD is associated with dopaminergic and 
serotonergic dysfunction in basal ganglia and limbic circuits.
Methods: Ten PD patients with fatigue (PD-F patients) and 9 PD patients without fatigue 
(PD-NF patients) had 18F-dopa PET. Seven PD-F patients and 8 PD-NF patients also had 
IIC-DASB PET. The two groups were matched for age, disease duration and severity, and 
daily intake of levodopa equivalent units. None had a history of depression or sleep 
disturbance.
Results: Using a region of interest (ROI) approach, we found that PD-F patients had 
significantly lower IIC-DASB binding than PD-NF patients in caudate, putamen, ventral 
striatum and thalamus. In all these structures, fatigue severity was inversely correlated with 
IIC-DASB binding. Striatal 18F-dopa uptake was similar in the two groups. Voxel-based 
analysis localised further IIC-DASB binding reductions in cingulate and amygdala, and 
reduced 18F-dopa uptake in caudate and insula in the fatigue group.
Interpretation: Fatigue in PD is associated with reduced serotoninergic function in basal 
ganglia and limbic structures. Insular dopaminergic dysfunction could also play a role. These
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findings imply that strategies to increases brain level of serotonin would be a rational 
approach for relieving fatigue symptoms in PD.
5.1. Introduction and rationale
Fatigue is common in PD and is a distinctive non-motor symptom (NMS). Definitions vary but 
in this set of work 1 have tried to address fatigue as it relates to the concept of central fatigue, a 
sense of overwhelming and sustained exhaustion, which is not necessarily related to physical 
effort. Prevalence studies suggest that such “disabling” fatigue is estimated to occur in about 
one-third of PD patients^^^’ Such fatigue has also been cited as a possible pre-motor non­
motor symptom of PD and adds to the current concept of a medley of NMS that may identify a 
“Parkinson at risk” population^^l Hagell and Brundin studied a cohort of 118 consecutive PD 
patients and assessed fatigue in this sample in a retrospective manner^ "^ ^^  and 18 (22%) reported 
significant and troublesome fatigue before any motor disturbance became apparent. Fatigue was 
exhausting and affected patients typically complain of a feeling of constant exhaustion or 
tiredness, either mental, physical, or both.
While fatigue overlaps with a degree of physical exhaustion however, as we have argued 
previously, the severity of mental fatigue does not correlate well with physical fatigue, 
suggesting that the two conditions are very likely to be caused by independent mechanisms in 
PD[28’ This notion is further supported by the fact that additionally, no direct relationship 
between presence of fatigue and type, dosage, and duration of anti-Parkinsonian medication has 
been found with any c e r t a i n t y ^ ^ s ,  52]  Conversely, as we have shown in our work in chapter 3, the 
concurrent presence of depression, aspects of nocturnal sleep disturbance, and autonomic 
impairment are all thought to exacerbate the subjective experience of fatigue. However, given
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that fatigue has been shown to occur independent of these NMS in PD, these factors cannot 
completely explain the high prevalence of central and “disabling” fatigue in PD. Furthermore, 
several authors have reported that symptoms of disabling fatigue are also reported in non­
depressed patients including untreated PD and is also experienced by patients with no complaint 
of sleep disorders^28.57] previous experiments would suggest that mechanisms in addition to 
“peripheral” ones are likely to be operative to explain the sense of disabling fatigue in PD. 
Looking at central/striatal pathways is therefore, reasonable as fatigue is linked to PD.
It has recently been proposed that basal ganglia dysfunction plays a role in the mechanism of 
fatigue in diseases of the central nervous system^^s] Several observations would support this 
view. Firstly, fatigue is an independently reported, highly prevalent NMS of PD; dominantly 
basal ganglia centred neurodegenerative disorder. Secondly, following bilateral posteroventral 
pallidotomy which was used for treatment of dyskinesias in PD, profound fatigue, sleepiness, 
changes in behaviour, and poor initiative in executive functions despite improvement in motor 
control has been reported^^ l^ Thirdly, in patients with multiple sclerosis, fatigue has been 
reported to be associated with reduced glucose metabolism in the frontal cortex and the basal 
ganglia^28] However, a recent study, the ELLDOPA trial, addressed assessment of fatigue among 
levodopa-naive PD patients and used striatal imaging as a surrogate marker and reported that 
levodopa naïve untreated patients with fatigue had similar striatal dopamine transporter uptake 
compared to patients without fatigue^ ^^ l^ These findings indicate that striatal dopaminergic 
mechanisms may not be operative and as such non-dopaminergic basal ganglia pathways are 
likely to be involved in fatigue generation in PD or, if dopaminergic dysfunction plays a role, it 
is likely to involve extra-striatal projections. Descriptions of these extra-striatal circuits have 
been described in chapter 2 and involve associative and limbic pathways. An alternative,
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neurochemical candidate substrate would be serotonergic pathways. Serotonergic pathways are 
known to be affected in Parkinson’s disease and this notion is supported by observations that 
serotonergic deficiency appears to be a pathophysiological factor in the genesis of chronic 
fatigue syndrome patients^^^J Accordingly, reduced serotonin transmission could have a role in 
the occurrence of fatigue in patients with PD.
In humans, in vivo imaging can be performed using positron emission tomography scans (PET) 
and specific ligands, which bind to and mark selective central neurochemicals. Dopaminergic 
terminal activity can be assessed by using Fluorine labeled ^^F-dopa PET, which has been widely 
validated as an in vivo marker. Figure 9 shows an ’^F-dopa PET image from a healthy volunteer 
and a patient with Parkinson’s disease showing the typical striatal loss of this marker.
Fig 9: ^^F-dopa PET image from a healthy volunteer and a patient with Parkinson’s disease 
showing the typical striatal loss of this marker
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At the MRC cyclotron unit at Hammersmith hospital in London, PET measurements of brain ^^ F- 
dopa uptake, are converted and then expressed as an influx constant, known as the Ki, which 
reflects the activity of the enzyme aromatic amino acid decarboxylase (AADC) in the axonal 
plexus. AADC is known to be present in high concentration in all catecholaminergic neurons and 
possibly in even greater concentrations in serotoninergic neurons.M easurem ent of ^^F-dopa 
uptake using Ki in different brain structures is thus likely to show the overall pattern of 
distribution of monoamine neuronal systems in areas of the brain known to be associated with 
dopamine, noradrenaline and serotonin i n n e r v a t i o n s ^ ^ ^ - s s ]
Serotonergic neuronal integrity and function can be measured by measurements of serotonin 
transport (SERT) availability by the ligand ^^C-DASB PET (llC-N,N-dimethyl-2-(2-amino-4- 
cyanophenylthio) benzylamine (DASB)). ^^C-DASB appears to have a high specificity and 
sensitivity for SERT but with much lower affinity for the dopamine and norepinephrine 
transporters and therefore represents a specific marker of serotoninergic i r m e r v a t i o n ^ ^ ^ l  The 
technique appears to be robust as additionally, studies have shown that ^^C-DASB binding 
potential values are consistent when tested for test-retest reliability conditions for most brain
regions^87]
The work described in this chapter describes a further project using '^F-dopa and ” C-DASB 
PET, a marker of serotonin transporter availability, to investigate in vivo the role of 
dopaminergic and serotonergic transmission in the pathophysiology of fatigue in a selected group 
of patient with severe fatigue compared to a group without. We hypothesised that patients with 
PD who experience central fatigue would show reduced serotonin and dopamine terminal 
function within basal ganglia and limbic circuits.
82
5.2. Patients and methods
Patients: In the final analysis, we screened forty PD patients with a clinical diagnosis of 
idiopathic PD (UK Parkinson’s Disease Society Brain Bank diagnostic criteria for Parkinson’s 
disease) for this study. These patients were recruited from the original cohort studied in chapter 
3. Similar exclusion factors applied. Specifically, for this study, patients with dementia (Mini 
Mental State Examination score <23), depression (as judged by Hamilton Rating Scale for 
Depression >16 and Beck Depression Inventory >9), and excessive daytime sleepiness (Epworth 
Sleepiness Scale >8) were excluded from our study.
A group of twenty patients were identified, and included 10 with significant and severe fatigue as 
judged by the Parkinson Fatigue Scale (PFS) devised by Brown et al^ ^^ l (Table 20). As described 
in the operational guidelines for the use of PFS-16, the presence of fatigue was defined as a score 
greater than 8 on the Parkinson Fatigue Scale (PFS-16). As described previously, the PFS-16 has 
specifically been designed to measure fatigue in a PD population taking in account possible 
overlapping with other motor and non-motor symptoms of PD. 10 others in the final cohort to 
undergo PET scans, had normal fatigue levels and would serve as case controls. The two groups 
were therefore classified according to the presence (n = 10) or absence (n = 10) of fatigue. These 
two groups (fatigue positive and fatigue negative) were matched for age, disease duration, daily 
intake of levodopa equivalent units (LEU), and underwent routine clinical assessments of motor 
function using the part 3 subscale of the Unified Parkinson’s disease rating scale (UPDRS) 
scores in both “o ff’ and “on” conditions. The demographics of this cohort are summarised in 
Table 19. All subjects had a stable response to their dopamine replacement therapy and none
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were taking any anti-depressants or any medications targeting serotoninergic and noradrenergic 
systems.
Levodopa equivalent (LEU) doses were calculated LEUs were calculated as follows based on the 
conversion paradigm: lOOmg levodopa= 2mg cabergoline = Img pramipexole or Img pergolide 
= 5mg ropinirole = 4mg rotigotine patch = 1 mg rasagiline x 0.5. The conversion factors below 
were used for controlled release levodopa and levodopa/carbidopa/entecapone combination: 
125mg controlled release levodopa = 65mg levodopa; 50mg levodopa/carbidopa/entecapone 
combination = 65 mg levodopa.
In the final scanning stage, eight PD patients with fatigue (PD-F) and seven PD patients without 
fatigue (PD-NF) had both 18F-dopa and 1IC-DASB PET. The remaining 5 patients had only one 
scan as they withdraw their consent after the first PET session. In summary, ten PD-F patients 
and nine PD-NF patients had 18F-dopa PET and eight PD-F patients and eight PD-NF patients 
had 1IC-DASB PET (Table 21).
The study received approval from the Ethics Committee of Hammersmith, Queen Charlotte’s & 
Chelsea and Acton Hospitals Trust. Permission to administer 18F-dopa and 1 IC-DASB was 
obtained from the Administration of Radioactive Substances Advisory Committee (ARSAC), 
UK. The project also had ethical approval fi-om the national research ethics committee for Kings 
College and Lewisham hospitals, London.
Since the main aim of this project was to compare fimction between PD patients with and 
without fatigue no healthy control subjects were scanned during this study. However, IIC-
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DASB PET findings for our two PD groups were compared with 9 healthy volunteers (all males, 
age 44.6± 5.5 years) from the Unit’s database.
5.3. PET procedure
PET scanning took place at the Cyclotron Building, Hammersmith Hospital, Hammersmith 
Imanet, GE Healthcare, London, UK, and all PET scans were performed using an ECAT 
EXACT HR+ (CTI/Siemens 962) camera, which covers an axial field of view of 15.5 cm and 
provides 63 transaxial planes. The tomograph has an axial resolution of 5.4 mm full width at half 
maximum (FWHM) and a transaxial resolution of 5.6 mm FWHM at 10 cm distance from the 
centre^ 20] Head position was carefully monitored with a video camera and by direct observation 
throughout. All patients had their levodopa medication stopped for at least 12h before PET, and 
dopamine agonists had been stopped 3 days before scanning.
The scanning protocol for 18F-dopa involved 3D acquisition over 94 minutes and 30 seconds 
following a bolus injection of 185 MBq of 18F-dopa. The scanning protocol for 1 IC-DASB 
involved 3D acquisition over 90 minutes and 30 seconds following a bolus injection of 450 MBq 
of 1 IC-DASB. Both 1 IC-DASB and 18F-dopa were supplied by Hammersmith Imanet.
5.4. PET Analysis
Parametric images of specific 18F-dopa uptake (Ki maps) were created on a voxel-wise basis 
using a standard multiple-time graphical approach over 30 to 90 minutes with an occipital 
reference input function^^ -^s ]^ integrated images (ADD images) of the dynamic time series of 
18F-dopa uptake collected over 30 to 90 minutes after intravenous tracer administration were 
also created for spatial normalization purposes. Spatial normalization of ADD images and Ki
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maps into standard Montreal Neurological Institute (MNI) stereotaxic space was performed 
using statistical parametric mapping (SPM) software package (SPM2, Welcome Department of 
Cognitive Neuroscience, Institute of Neurology, London, UK) implemented in MatlabS. First the 
ADD images were normalized to a smoothed 18F-dopa ADD image template in MNI space 
created in-house from healthy control subjects. Then the transformation parameters were applied 
to the respective 18F-dopa Ki maps. Parametric images of specific 1 IC-DASB binding potentials 
[BPND (non-displaceable) in consensus nomenclature^^®  ^ were generated on a voxel wise basis 
for the whole brain using a basis function implementation of the simplified reference region 
compartmental model with the cerebellum providing the reference tissue input function.
Integrated ADD images of 1 IC-DASB uptakes were also created for spatial normalization 
purposes. ADD images and parametric images of 1 IC-DASB BPND were then normalized, 
using SPM2 software, to a smoothed 1 IC-DASB ADD image template in MNI space created in- 
house from healthy control subjects.
5.5. Extraction of data from region of interest (ROI)
To extract ROI data we used a standard object map in MNI space. The standard object map 
contained regions defined for caudate nucleus, putamen, ventral striatum, thalamus, and median 
raphe. These ROIs had been free hand traced using ANALYZE 8.1 software (Mayo clinic, MN), 
onto the single subject MRI in MNI space available in SPM2. The same standard object map was 
applied to each spatially normalized image of 18F-dopa Ki or 1 IC-DASB BPND and 
corresponding ADD images. Visual inspection of each plane for both images was made to ensure 
correct placement of the object regions over the correspondent structures. After applying target 
regions to structures, 18F-dopa Ki and 1 IC-DASB BPND values were quantified using 
ANALYZE 8.1.
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5.6. Voxel-based analysis
SPM2 software was used to localize significant changes in tracer uptake between PD-NF and 
PD-F patients at a voxel level. Normalized parametric images of 18F-dopa Ki and 1 IC-DASB 
BPND were spatially smoothed using a 6 x 6 x 6 mm (full-width at half maximum) isotropic 
Gaussian kernel. For each tracer, between-group comparisons were performed by using weighted 
contrasts to localize significant decreases in mean voxel tracer uptake in PD-F patients compared 
to PD-NF patients. The contrast was used to generate maps of Z scores on a voxel basis using the 
general linear model. The statistical maps were visualized at a threshold p < 0.01 (Z score = 
2.33), and any resulting cluster with a p <0.05 is reported.
5.7. Statistical analysis
Statistical analyses of clinical data were performed with InStat3 for Macintosh (University of 
Medicine and Dentistry, NJ, USA). Comparisons between groups were made using a non- 
parametric unpaired test (Mann-Whitney statistics). Correlations between PET findings and 
variables of interest were tested with Spearman rank correlation.
5.8. Results
Severity of fatigue in the whole group of 20 PD patients did not correlate with age (Spearman r 
=0.24), disease duration (Spearman r =0.28), LEU intake (Spearman r =0.32), UPDRS motor 
subscale-3 score in off stage (Spearman r =0.32), or UPDRS-3 score in on stage (Spearman r 
=0.08).
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Regional mean 1 IF-dopa Ki values in PD-F patients and PD-NF patients are shown in Table 2. 
PD-F patients and PD-NF patients had similar mean 18F-dopa uptake in putamen, ventral 
striatum, thalamus, and median raphe. PD F patients had a trend towards lower mean 18F-dopa 
uptake in caudate than PD-NF patients (p=0.095). Categorical comparisons with SPM between 
PD-F patients and PD-NF patients localized clusters of significant decreases in 18F-dopa Ki in 
caudate bilaterally and left insula (Table 22, Figure 10) in the cohort of PD-F patients.
1 IC-DASB findims
For one PD-F patient spatial normalization of their parametric BP image to the 1 IC-DASB 
templates was unsuccessful and this case was excluded from the analysis. PET findings were 
also compared with those of 9 healthy volunteers (M/F= 6/5, age 44.6± 5.5 years). Regional 
mean 1 IC-DASB BPND values in normal subjects, PD-F patients, and PD-NF patients are 
shown in Table 20. Control subjects had higher 1 IC-DASB BPND values than both groups of 
PD patients in the caudate, putamen, ventral striatum and thalamus. However, in all these areas, 
PD-NF patients had significantly higher BPND values than PD F patients. Categorical 
comparisons with SPM between PD-F patients and PD-NF patients localized clusters of 
significant relative bilateral decreases in 1 IC-DASB BPND in caudate, putamen, ventral 
striatum, thalamus, cingulate gyrus, and amygdala (Table 21) in the cohort of PD-F patients.
5.9, Clinical correlations
Correlation analyses between clinical characteristics of PD patients and regional 1 IC-DASB 
BPND or 18F-dopa Ki are summarized in Table 22. Within the PD cohort, individual IIC-
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DASB BPND values inversely correlated with PFS-16 scores in all the examined ROIs. 1 IC- 
DASB BPND values in the raphe were also inversely correlated with disease duration.
5.10. Discussion
Our a priori hypothesis in this pilot exploratory study was that PET imaging using 18F-dopa and 
1 IC-DASB binding would uncover abnormalities in dopaminergic or serotonergic or both 
systems in the striatal or extra-striatal locations in PD patients with fatigue. Given the small 
number of patients that can be scanned in the PET facility owing to major cost implications as 
well as tolerability of an uncomfortable process in disabled PD patients, we were extremely 
stringent in our inclusion criteria for patients and only those with severe fatigue and no 
depression, daytime sleepiness were selected and matched in a fatigue normal group. 
Additionally we took care that both groups were matched in terms of their motor disability. As 
expected this took substantial time and resource to compile.
The key finding of this study has shown that the presence of fatigue in PD is associated with 
profound serotoninergic denervation in the basal ganglia and associated limbic circuits for the 
first time. With an ROI approach, we found that SERT availability, as measured by 1 IC-DASB 
binding, was significantly reduced in both dorsal and ventral striatum, and in the thalamus of 
PD F patients compared to PD-NF patients. In each of these regions, individual 1 IC-DASB 
BPND values from the whole cohort of PD patients were inversely correlated with respective 
PFS-16 scores, suggesting a close relationship between SERT availability and severity of fatigue. 
Voxel based analysis comparing PD-NF and PD-F groups confirmed and extended the findings 
from the ROI analysis. In the PD-F group, clusters of significant decreases in 1 IC-DASB BPND 
were localized in the whole striatum, in the thalami, and in additional cortical regions, including
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cingulate gyms (Brodmann areas 24 and 32 bilaterally), right paracentral lobule (Brodmann area 
31), left insula, and right amygdala.
An explorative voxel-based comparison between 18F-dopa images of PD-NF and PD-F patients 
localized significant (p<0.01) 18F-dopa uptake reductions in the left caudate and left insula in 
the latter group (Figure 10). An ROI analysis showed a trend for lower 18F-dopa Ki values in the 
caudate (averaged right and left) of PD-F patients compared to PD-NF patients (p=0.094) but no 
other differences between the two groups. This finding is in line with the study reported by 
Schfitto et al as part of the ELLDOPA study where early PD patients with and without fatigue 
showed similar striatal dopamine transporter binding using SPECT study.^^ l^ jf  one considers 
these findings together, these findings suggest while dopaminergic striatal (caudate) dysfimction 
may be in part operative in the pathogenesis of fatigue in PD, overall the findings are against 
dopaminergic nigrostriatal degeneration per se being the only and principle factor in the 
pathogenesis of fatigue in PD. In addition, however, one will also have to consider that our study 
indicates that PD-F patients show a reduced 18F-dopa uptake in the insular cortex and thus a 
possible link between fatigue and loss of extra-striatal dopaminergic function.
As discussed previously, the PD-NF and PD-F patients were carefully matched for gender, age, 
disease duration, daily LEU, and severity of motor symptoms, as measured by UPDRS, in both 
“off’ and “on” condition (Table 17). PD patients with dementia, overt depression, and sleep 
disturbances were not included in the study and so we feel that the PET findings observed in the 
PD-F groups should be specific for fatigue in PD.
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1 IC-DASB has high specificity and sensitivity for SERT (nanomolar affinity) and much lower 
affinity for the dopamine and norepinephrine transporters (micromolar affinity)^^?] ^  jg therefore 
likely that decrease of 1 IC-DASB binding reflects a loss of SERT-expressing terminals in the 
corresponding areas of the brain, indicating degeneration/dysfunction of the serotoninergic 
pathways. However, one could argue that low 1 IC-DASB binding might be a reflection of the 
down regulation of SERT expression rather than loss of SERT-expressing terminals. We cannot 
completely refute this issue although, several post-mortem studies have now demonstrated 
depletion of serotonin and SERT levels in the striatum as well as in extra-striatal areas in PD 
patients^^ '^^2] particular, Kish and colleagues have recently reported that SERT and other 
serotoninergic markers, including serotonin itself were significantly reduced in the striatum of 
PD patients compared to controls^^^l In their study, there was a preferential loss of SERT and 
serotonin in caudate nucleus compared with the putamen area. Additionally, these workers also 
reported that changes in striatal SERT binding in PD brains was reflective of an actual reduction 
in levels of SERT protein^^^l
The basal ganglia receive sensory and motor input from all cortical areas and are a relay in 
neuronal pathways processing emotional, motivational, associative and cognitive functions. A 
major role of the basal ganglia is to integrate sensorimotor, associative, limbic and motor 
information into efficient thought and action^^ l^ ^  ^as been suggested that structural lesions 
and/or changes in the neurotransmitter balance within the basal ganglia and associated structures 
disrupt the process of integration of limbic input concerning emotional status and consequent 
motor output^^8] Dissociation of motivation from executive motor movement could lead to a 
tendency of reluctance to act resulting in experiencing a feeling of fatigue^ '^ l^ Our findings 
provide strong evidence in support of this pathophysiological model of fatigue in PD. PD-F
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patients showed reduced SERT expression in the main components of the basal ganglia including 
the ventral striatum which is a key area bridging neuronal circuits and where the limbic-to-motor 
integration is thought to occur^^^l
Decreases of 1 IC-DASB binding in PD-F patients were also found in limbic structures 
including: (i) Brodmann areas 24 and 31, corresponding to the ventral portion and the isthmus of 
the cingulate gyrus respectively, both involved in emotion processing; (ii) Brodmann area 32, 
corresponding to the dorsal anterior cingulate cortex anterior, which is involved in decision 
making processes; and (iii) the amygdala, which is involved in the processing of emotional 
reactions and emotional memory as well as spatial and motor learning.
The insular cortex is also a component of the limbic system. It has reciprocal connections with 
anterior cingulate, amygdala, basal ganglia and prefrontal cortex and could represent a center of 
multi-modal sensory-motor-limbic integration^^^l The insular area is also known to play a role 
in regulating autonomic functions and control. Changes in 1 IC-DASB binding and 18F-dopa 
uptake were observed in the left insular cortex of PD-F patients suggesting an asymmetric 
pathophysiology. This is somewhat unexpected and difficult to explain. This apparent 
lateralization of PET findings could be due to the fact that our study lacks power to show robust 
differences in this regard due to the relatively small number of patients in this study.
Dysfunction of brain serotoninergic pathways has been reported in patients with chronic fatigue 
syndrome (CFS) without PD. Using the PET ligand llC-(+)McN5652, Yamamoto and 
colleagues reported reduced SERT binding in the rostral subdivision of anterior cingulate area 
(Brodmann areas 24/32) in CFS patient compared with controls^^^J jjj another study, Cleare and
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colleagues found widespread reduction of llC-WAY-100635, a specific radioligand for 
serotonin 5-HTlA receptors, in CFS patients when data was compared to controls^^ l^ jn their 
study of CFS patients, reductions in 1IC-WAY-100635 binding were particularly marked in the 
hippocampus bilaterally along with involvement of other limbic areas such as amygdala, insular, 
and anterior cingulate. This suggests overlap of anatomical sites between our study and the 
study of Cleare et al
What might this pilot exploratory study mean in relation to treatment of fatigue in PD? Selective 
serotonin reuptake inhibitors (SSRIs) are commonly used in the treatment of CFS and are often 
used in PD patients with history of fatigue possibly for treatment of depression. In light of the 
data from our study, however, the marked reduction in SERT binding in PD-F patients raises 
doubt about the use of SSRIs if these are used to treat fatigue in non-depressed PD patients. 
SSRI’s increase synaptic levels of serotonin by inhibiting SERT activity and may be counter­
productive in a situation where SERT activity is attenuated as seen in our study in PD-F cases. 
To date the dopamine transported blocker, methylphenidate, at a dose of 10 mg three times a day 
has been examined in a randomized placebo controlled trial and is the only drug that provides a 
degree of level 1 evidence showing significant improvement of fatigue in PD patients^^^l jf  our 
finding of reduced serotoninergic activity in PD with fatigue is confirmed in larger groups of 
patients and in pathological studies, alternative strategies to increases brain level of serotonin 
should be tested in these patients.
There are of course limitations to a study such as this. While PD-NF and PD-F patients were age- 
matched, our healthy control subjects used for the IIC- DASB PET comparisons were on 
average 20 years younger than the PD patients. This is because of difficulties in obtaining older
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control groups for invasive and radiation linked procedure such as PET. Buchert et al have 
suggested an age-related decline in the availability of SERT when measured with PET and 
SPECT while the percentage reduction in SERT availability per decade across published series 
varies from 2% to 10.5% (median 50th percentile 4.5%)^ 8^1 Based on these observations one 
could calculate that the maximum decline in 11C- DASB binding in our PD cohorts (with and 
without fatigue) that could be linked to age related decline, is around 21%. This reduction is 
however, is much less compared to the striking decline observed in this study, where the PD-F 
patients showed a reduction of 1 IC-DASB binding close to 80% of the control mean in most of 
the regions assessed by ROI approach (Table 20). We can therefore, argue the case that the 
reduction in 11C- DASB binding observed in the PD-F groups is unlikely to be explained by 
aging alone.
While findings from this study indicate that the level of dopaminergic nigrostriatal dysfunction 
does not differentiate PD patients with and without fatigue, they do not exclude loss of striatal 
dopamine playing a role in its pathogenesis. Although fatigue is associated with more severe 
involvement of the serotoninergic system in PD patients, it is likely that changes in the 
serotonin/dopamine balance within the basal ganglia also contribute and may cause 
decompensation within the limbic and associative circuits.
Finally, by excluding patients with dementia, depression, and sleep disturbances we have 
reduced the effects of possible confounding factors and shed light on the pathogenesis of 
“primary” fatigue in PD. However, all these other factors are known to exacerbate the subjective 
experience of fatigue and may in some case is predictors of fatigue as shown in our study in 
chapter 3. In some cases, these non-motor symptoms may also be the predominant cause for
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fatigue. It is possible that distinct neurochemical substrates could underlie these situations and 
further studies are clearly needed to address NMS such as excessive daytime sleepiness using a 
similar approach as in this study.
Table 18: Descriptive demographic details and fatigue and UPDRS scores in fatigue 
positive vs fatigue negative groups. UPDRS = Unified Parkinson’s disease rating scale
12C- 18 F- Disease PFS UPD UPD
Patient Gen DASB Dopa Age duration 16 RS RS
Number der PET PET (years) (years) LEU score OFF On
PD-NF group
1 M X X 53 7 450 1 30 15
2 M X X 71 4 200 1 42 25
3 M // X 63 3 590 2 32 28
4 F X X 46 3 750 3 33 15
5 F X X 76 4 915 5 36 27
6 M X X 52 2 835 5 26 19
7 M X X 77 6 715 6 40 25
8 M X // 70 4 550 6 36 20
9 F // X 59 4 550 1 32 18
10 F X X 69 4 250 1 28 17
632.6 580 ± 4.3 ± 33.5 20.9
Mean ± SD ±10.7 4.1 ± 1.4 235 2.4 ±5.1 ±4.9
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PD-F group 
11 M X X 69 5 750 10 35 25
12 F X X 57 3 785 10 22 14
13 F X X 66 7 1480 11 42 22
14 M // X 59 5 550 13 42 25
15 M X X 55 3 280 13 32 17
16 F x^ X 58 6 635 14 36 17
17 M X X 77 8 600 14 38 21
18 M X X 70 3 1000 15 34 23
19 M X X 66 11 1135 16 38 31
20 F // X 70 4 520 16 30 18
Mean ± SD
64.7 ± 
7.2 5.5 ±2.6
773 ± 
348
13.2
± 2.3
34.9
± 6
21.3
±5-
a in this patient the spatial normalization of the individual parametric image to the llc-dasb 
template was unsuccessful and the patient was excluded from the analysis.
F=female; LEU = levodopa equivalent units; M = male; PFS-16 = Parkinson's Fatigue Scale; 
X = performed; // = not performed; PD-NF = Parkinsons' disease without fatigue; PD F = 
Parkinson's disease with fatigue.
Table 19: Regional mean ^*F-dopa Ki values (± Standard Deviation) in Parkinson’s disease 
patients with (PD F) and without (PD-NF) fatigue
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PD-NF PD F
(n=9) (n=10)
Caudate 0.0082 ±0.0014 0.0071 ±0.0016*
Putamen 0.0051 ±0.0010 0.0045 ± 0.0009
Ventral striatum 0.0089 ±0.0013 0.0084 ±0.0013
Thalamus 0.0026 ± 0.0008 0.0025 ± 0.0008
Raphe 0.0038 ± 0.0007 0.0040 ± 0.0008
Table 20: Areas of significant decreases in C-DASB binding potential in Parkinson’s 
disease patients with fatigue compared to Parkinson’s disease patients without fatigue
Z score MINI coordinates Area p-value
(corrected)
X Y Z
5.13 25 5 9 R putamen <0.001
4.83 -26 2 8 L putamen <0.001
4.80 14 9 12 R caudate <0.001
4.60 -14 12 6 L caudate <0.001
4.40 -34 -12 20 L insula <0.001
4.40 -10 6 40 L cingulate BA 24/32 <0.001
4.07 4 -14 42 R cingulate BA 24/32 <0.001
3.83 8 -8 10 R thalamus <0.01
3.58 -10 -14 6 L thalamus <0.01
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3.24 4 -28 46 Right
paracentral
lobule
<0.01
3.20 18 -2 -22 L Amygdala
<0.01
Table 21. Correlation analysis for regional "C-DASB binding potential and clinical 
characteristics in the total group of patients with Parkinson’s disease (n 0=015)
Spearman Rank correlation coefficient (rho)
Caudat
e
Putame
n
Ventral striatum Thalamus Raphe
Age -0.29 -0.32 -0.27 -0.48 -0.61*
Disease duration -0.38 -0.29 -0.40 -0.31 -0.54*
UPDRS OFF -0.40 -0.38 -0.35 -0.42 —0.46
Table 22. Correlation analysis for regional ^^F-Dopa Ki and clinical characteristics in the 
total group of patients with Parkinson’s disease (w 0=019)
Spearman Rank correlation coefficient (rho)
Caudat
e
Putame
n
Ventral striatum Thalamus Raphe
Age -0.33 -0.05 -0.19 0.23 -0.25
Disease duration -0.07 -0.10 -0.04 0.04 -0.21
UPDRS OFF -0.56* -0.51* -0.28 -0.26 —0.33
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Figure 10: Reduced ^^F-Dopa uptake in patients with Parkinson’s disease with fatigue. 
Projections of statistical parametric maps showing areas of significant decreases in *^F- 
Dopa are seen in the left insula and left temporal gyrus.
SPM  analysis 
A reas o f  reduced ^^F-dopa uptake
P < 0.001
9  P D  f a t i g u e  <  6  P D  w i t h o u t  f a t i g u e
Figure 11: ADD images of 1 IC-DASB binding potential (BPND) from a normal subject, a 
Parkinson’s disease patients without fatigue, and a Parkinson’s disease patients with 
fatigue. The colorstripe indicates binding potential values for 1 IC-DASB.
PD without fatigue
■ PD with fatigue
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CHAPTER 6
Conclusions and comments on prevalence, features and pathophysiological basis of fatigue 
in Parkinson’s disease
6.1. Overall Comments
For many years, like many NMS of PD, fatigue has been poorly recognized and researched. 
Since the description in Hoehn and Yahr’s seminal paper in 1967, it took almost 30 years for the 
issue of fatigue in PD to be rekindled^ '^^’ We are now aware that fatigue is common in PD and 
is a specific and distinctive non-motor symptom (NMS). Over the years the confounding issue 
about the definition of fatigue in PD has become clearer and the concept of central fatigue is now 
reasonably well established and is related to a sense of overwhelming and sustained exhaustion, 
which is not necessarily related to physical effort. Availability of specifically validated scales 
that are now recommended on the basis of critiques by learned societies helps us and uniformity 
of diagnosis of fatigue in clinical practice and avoids confusion with the two major confounders, 
depression and excessive daytime sleepiness^^^l
The first of my experimental chapters (Chapter 3) deals with addressing point prevalence and 
correlates of fatigue from a cohort selected for non-motor symptoms based studies. In this study 
fatigue was assessed in an unselected cohort of 135 patients across all motor stages of 
Parkinson’s using the fatigue visual analog scale which is used by interacting with the affected
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persons with specific emphasis on the severity of the tiredness they experienced using the VAS 
where 0 on the scale signified highest amount of fatigue and 100 signified complete absence of 
tiredness. This scale known as the fatigue impact scale for daily use (D-FIS) has been validated 
for Parkinson’s and its clinimetric details have been published and is also included in the Task 
force critique document^'^^l In this study fatigue was additionally assessed while completing the 
non-motor symptom scale (NMSS), which addresses fatigue, by severity (from 0 to 3) and 
frequency (from 1 to 4), in the question 4 of the sleep/fatigue domain. This study included 
patients from all stages in PD and 55.56% were from early PD cases, including untreated PD 
(mostly HY stage 1-1.5 cases). When the sample of PD patients was stratified by HY stage, 
mean fatigue score in HY stage 1 was less severe than fatigue in moderate (56.83±17.16) and 
severe cases (54.94±26.44) (p=0.004). The patient base used in this study was based on a “real 
life” population and broadly representative of the PD population as a whole with a mean age of 
69.7±10.52 years and an age range of 35 to 88 years. This observation is supportive of existing 
data that in PD, fatigue occurs in early disease and in untreated PD cases, as well as in young and 
“old” PD cases as part of the disease process itself but the prevalence of fatigue rises as the 
disease progresses as also shown in the PRIAMO study^^^l This observation and literature study 
on this issue as described in chapter 3 leads me to conclude that in majority of PD patients 
afflicted with fatigue, fatigue is intrinsic to the disease and can be present right at the onset of the 
motor syndrome.
The second aspect of the study was to address defining the “correlates” or “predictors” of fatigue 
specifically excessive daytime sleepiness (EDS) as well as depression, apathy and general 
tiredness. These were assessed using clinical scales such as HADS (anxiety and depression), 
NMSS (sleep and EDS) and CIRS (tiredness). Spearman rank correlation coefficient measures
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were calculated between the various variables and fatigue scores as shown in Table 15 in 
Chapter 3.
The data indicate that the motor state and disease severity (UPDRS 3 and HY), anxiety and 
depression scores (HADS anxiety, HADS depression), mood, sleep from the NMSS scores, 
HrQol as indicated by PDQ-8 assessments were highly significantly associated with fatigue in 
PD (all p < 0.0001). This also may indicate that presence of significant fatigue may predispose to 
developing the aforesaid NMS such as anxiety, depression and sleep problems. This does not 
also mean that fatigue may not occur independent of these NMS. As shown in studies by Alves 
et al and Schiffito et al and others, fatigue has been well documented in untreated non-depressed 
and non-drowsy PD patients^^^’"*^1 ' However, the clinical issue is that in studies related to fatigue 
in PD therefore, specific attempts must be made to account for depression, anxiety and sleep 
dysfimction to avoid confounding observations. The association of fatigue with disease severity 
and motor state is in line with several observations including the PRIAMO study^^^l
The clinical studies then move on to chapter four where pathopysiological mechanisms 
underlying fatigue is explored. In this pilot exploratory work we have addressed a possible 
peripheral component mediated by peripheral sympathetic nervous system integrity based on the 
assumption that peripheral autonomic dysfunction has been shown to be related to fatigue in 
other conditions.
This thus confounds the issue of “independent” fatigue in PD and concurs with the studies, 
which have suggested that sleep disorders, depression and disease stage may be possible 
secondary causes of fatigue in individuals with PD. In PD, the autonomic nervous system (ANS)
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which regulates the cardiovascular system is known to be affected early as suggested by Braak 
whose “bottom up” progression of Lewy body pathology would suggest that autonomic 
dysfunction mediated through the brainstem medullary centres. As such autonomic dysfunction 
may even arise in the pre-motor stage of Parkinson’s.
The availability of SPECT scans allows us to explore the use of meta-iodobenzylguanidine 
(MIBG) scans. Decreased cardiac uptake of meta-iodobenzylguanidine (MIBG), a physiological 
analog of norepinephrine, on *^^I-MIBG myocardial scintigraphy suggests a sensitive way of 
detecting cardiac sympathetic dysfunction, a technique widely used in cardiac clinical care. Our 
hypothesis was therefore, that if peripheral autonomic dysfunction (mediated by (peripheral 
sympathetic dysfunction) was indeed underlining the development of fatigue in PD, a group of 
patients who have fatigue would demonstrate cardiac MIBG uptake abnormalities in contrast to a 
group without fatigue who should demonstrate normal uptake. For recruitment to this study we 
use the well-defined cohort already studied as described in chapter 3 who were fiirther defined in 
relation to fatigue by using the PFS-16 scale. The PFS-16 scale, developed by Brown and 
colleagues is widely used and specifically addresses the confounder issue of depression and 
sleepiness and is recommended for use by the MDS task force. Using this scale allowed us to 
further define fatigue positive and negative cases as accurately as clinically possible. All together 
50 cases were selected 25 of who had significant fatigue on D-FIS while 25 did not. PFS-16 was 
applied to this cohort to further confirm the fatigue state and then they underwent MIBG cardiac 
scanning using locally established clinical protocol and documentation of their uptake ratios as 
described in chapter 4. Owing to the rigorous procedure, logistic difficulties with travel and off 
and on motor state and radiation relates issues, we were able to complete the scanning protocol, 
which also included a MIBI cardiac scanning to rule out any confounding vascular component,
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we were only able to scan 10 patients in each group. As per local laboratory values, a ratio of 
R1:R2 of 1.5 or less was regarded as low uptake of MIBG and 1.5 was taken as the cut off value 
and we could detect no differences in MIBG uptake ratios between the fatigue positive and 
negative groups.
Although the sample size is small, nevertheless to our knowledge this is the first exploratory of 
its kind and suggested at least in part that fatigue in PD may not be related to peripheral 
sympathetic outflow. A central patho-physiological basis therefore would need to be explored. 
Several other correlations were documented as described in chapter 4 but the extrapolations from 
these observations are limited by the fact that there was very small number of patients in this 
specific project.
This then leads us to the final experimental chapter, which is set out to explore, in part, a 
possible central pathophysiological basis for fatigue in PD focusing on dopaminergic and 
serotonergic mechanisms in vivo. The rationale for addressing both dopaminergic and 
serotonergic mechanisms rest on the fact in the ELLDOPA trial which addressed assessment of 
fatigue among levodopa-naive PD patients and used striatal imaging as a surrogate marker, 
reported that untreated PD patients with fatigue had similar striatal dopamine transporter uptake 
compared to patients without fatigue '^^ l^ This finding suggest that striatal dopaminergic 
mechanisms may not be the dominant basis of central fatigue in PD and non-dopaminergic basal 
ganglia pathways are likely to be involved as well as extra-striatal dopaminergic projections. As 
such and alternative, neurochemical candidate substrate would be serotonergic pathways, which 
are known to be affected in PD. Indeed serotonergic deficiency appears to be a 
pathophysiological factor in the genesis of fatigue in chronic fatigue syndrome patients.
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We sought to explore this hypothesis in a collaborative venture with the positron emission 
tomography (PET) imaging centre at Hammersmith Hospital campus at Imperial College with 
Professor David Brooks and Dr N Pavese. In humans, in vivo imaging can be performed using 
specific ligands which bind to and mark dopaminergic terminal activity by using * ^ Fluorine 
labeled ^ ^F-dopa PET and serotonergic neuronal integrity and fimction by measurements of 
serotonin transport (SERT) availability by the ligand ^^C-DASB PET (llC-N,N-dimethyl-2-(2- 
amino-4-cyanophenylthio) benzylamine (DASB)).
We needed to scan a group of patients with (PD-F) versus without fatigue (PD-NF) as in the 
previous study and additionally be stringent in terms of matching for motor state as well as 
excluding those with significant depression or excessive daytime sleepiness. This would suggest 
that there was likely to be considerable number of screen failures. An exploratory power 
calculation suggested we needed at least 8 patients in each group to reach valid comparison using 
parametric analysis of PET images. We therefore, screened forty PD patients with a clinical 
diagnosis of idiopathic PD (UK Parkinson’s Disease Society Brain Bank diagnostic criteria for 
Parkinson’s disease) who were recruited from the original cohort studied in chapter 3. Similar 
exclusion factors applied. As mentioned previously for this study, we excluded patients with 
dementia (Mini Mental State Examination score <23), depression (as judged by Hamilton Rating 
Scale for Depression >16 and Beck Depression Inventory >9), and excessive daytime sleepiness 
(Epworth Sleepiness Scale >8). From this cohort of 40, we could select finally a group of 10 
fatigue positive (PFS-16 rated) and 10 fatigue negative cases that were matched for age, disease 
duration, motor Unified Parkinson’s disease rating scale (UPDRS -  3) and daily intake of
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levodopa equivalent units. As indicated in the operational guidelines for the use of PFS-16, the 
presence of fatigue was defined as a score > 8 on the Parkinson Fatigue Scale (PFS-16).
Categorical comparisons with SPM between PD-F patients and PD-NF patients localized clusters 
of significant decreases in 18F-dopa Ki in caudate bilaterally and left insula (as described in 
chapter 5, Table 20, Figure 10) in the cohort of PD-F patients. For one PD-F patient spatial 
normalization of their parametric BP image to the IIC-DASB templates was unsuccessful and 
this case was excluded from the analysis. PET findings were also compared with those of 9 
healthy volunteers (M/F= 6/5, age 44.6± 5.5 years). Control subjects had higher IIC-DASB 
values than both groups of PD patients in the caudate, putamen, ventral striatum and thalamus. 
However, in all these areas, PD-NF patients had significantly higher BPND values than PD-F 
patients. Specifically, we localized clusters of significant relative bilateral decreases in IIC- 
DASB BPND in caudate, putamen, ventral striatum, thalamus, cingulate gyrus, and amygdala 
(Chapter 5, Table 22) in the cohort of PD F patients. This suggested a dominant central striatal, 
limbic/thalamic serotonerigc dysfunction underlying fatigue in PD.
Although the study sample size is small, the differences were still robust suggesting that at least 
in a proportion of PD patients with severe and draining fatigue, striatal and limbic serotonergic 
mechanisms are likely to underlie the genesis of fatigue. There is a differential pattern in that 
raphe serotonergic uptake is relatively undisturbed. The emerging biochemical deficit in fatigue 
is therefore, likely to be a combination of striatal and thalamic serotonergic deficit with 
additional extra-striatal (insular) dopaminergic dysfunction.
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6.2. Clinical Implications
Fatigue remains a poorly understood and poorly categorized NMS of PD although now 
recognised to be an independent NMS and clinically evaluated by a number of scales validated 
for PD. In addition, however, depression, anxiety and sleep disorders are indeed significantly 
associated with fatigue and may indeed be predictors of fatigue in PD. Peripheral autonomic 
dysfimction in the form of sympathetic dysautonomia is unlikely to be a causative factor while 
central serotonergic and dopaminergic mechanisms are operative. This has major therapeutic 
implications in PD and there is some indirect evidence in support of this issue. Rotigotine patch 
is a transdermal dopamine agonist patch which has been reported to lead to improvement of 
motor symptoms as well as sleep in PD in the RECOVER s t u d y S e c o n d a r y  outcome variable 
analysis of this study reveals a prominent beneficial effect of Rotigotine patch on fatigue but not 
placebo in the non-motor symptoms scale. Rotigotine is known to have serotonin receptor 
affinity (5HTia ++). Levodopa is also known to be effective and has considerable serotonergic 
activity. We feel therefore, further studies are required in future with serotinergic agents (either 
release enhancing pro-drugs or potent receptor agonists such as triptans) to address treatment of 
fatigue, one of the most disabling problems in some people with Parkinson’s.
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